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ABSTRACT 
GROUP II METABOTROPIC GLUTAMATE RECEPTORS 
IN THE BASAL AMYGDALA REGULATE SLEEP AND 
FEAR-INDUCED ALTERATIONS IN SLEEP 
Enheng Dong 
Eastern Virginia Medical School and Old Dominion University, 2010 
Director: Dr. Larry D. Sanford 
Glutamate is a major excitatory neurotransmitter in the brain and it has been 
recognized as playing an essential role in activating and maintaining arousal. Group II 
metabotropic glutamate (mGlu II) receptors are expressed in the amygdala, a brain 
structure important in the regulation of stress and anxiety as well as in the regulation of 
sleep and arousal. Our lab has found that the central nucleus of the amygdala (CNA) is 
involved in the emotional modulation of sleep. The basal amygdala (BA), which has 
direct connections with the CNA, is involved in conditioned fear and fear extinction. 
However, the potential role of the BA in the regulation of sleep has received little 
attention. In this study, we investigated the role of mGlu II receptors in sleep and 
stress-induced alterations in sleep. 
In work detailed in chapter II, either the mGlu II receptor agonist LY379268 (LY37) 
or antagonist LY341495 (LY34) was microinjected into the BA in rats. The effects on 
sleep were recorded and analyzed. It was found that LY37 suppressed rapid eye 
movement sleep (REM) without significantly altering non-REM sleep (NREM) or total 
sleep. In contrast, microinjection of LY34 at a high concentration (60 nM) increased 
arousal by suppressing REM and NREM. 
In work detailed in chapter III, rats received conditioned fear and extinction training 
and LY34 or vehicle was injected into the BA immediately before fear extinction 
training. It was found that rats injected with LY34 demonstrated greater fear responses in 
the earlier periods of extinction training and showed less fear responses later in the 
session when compared to the control group. LY34 also ameliorated sleep disturbances 
following fear extinction training. 
These results demonstrate that the BA may be a brain area that exerts a regulatory 
effect on sleep, especially REM. mGlu II receptors in the BA may be essential for 
regulating sleep. Suppression of these receptors may increase arousal and contribute to 
the improved performance of fear extinction. These data expand our knowledge on the 
role of the amygdala in the regulation of sleep. They may also provide prospects for the 
treatment of anxiety disorders, such as posttraumatic stress disorder (PTSD). 
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Introduction to the Study 
Stress alters homeostasis and induces multiple physiological responses. It is 
considered to be an important contributor to various health problems (Korte et al., 2005). 
The effects of stress on behaviors during wakefulness can be obvious. However, sleep in 
the period following a stressful event may also be affected. In recent years, the effects of 
stress on sleep have received considerable attention and a number of studies have been 
performed. In our lab, conditioned fear has been used as a model for studying stress 
related to fear and anxiety and its impact on sleep (Sanford et al., 2003; Tang et al., 2005). 
We focus on the amygdala because it is an important emotional center in the brain 
(LeDoux, 1992) and it plays an important role in conditioned fear (Davis, 1997). In 
conditioned fear, both training with footshock and shock associated contexts can alter 
subsequent sleep patterns, especially rapid eye movement sleep (REM) (Sanford et al., 
2003). The amygdala, in particular the central nucleus of the amygdala (CNA), plays a 
significant role in regulating sleep and in mediating the effects of stress on sleep (Sanford 
et al., 1998; Sanford et al., 2002; Tang et al., 2005). In addition, the basal amygdala (BA) 
has a direct connection with the CNA (Davis and Whalen, 2001). Blockage of the BA 
impairs fear learning (Ono et al., 1995; Maren et al., 1996), suggesting that the BA is 
The model journal for this dissertation is Brain Research. 
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involved in the regulation of emotion. Furthermore, electrical lesion of the basolateral 
amygdala (BLA, a complex that includes the BA, the lateral amygdala (LA) and the 
accessory basal amygdala (AB)) suppresses wakefulness and increases non-REM sleep 
(NREM) and REM, suggesting that the BA may be important in the amygdalar regulation 
of sleep. 
Glutamate is the major neurotransmitter in the amygdala, especially in the BA (Sah 
et al., 2003). It is implicated in stress and anxiety (Bergink et al., 2004; Cortese and Phan, 
2005). For example, suppression of N-methyl-D-aspartate (NMDA) receptors in the BLA 
impairs the acquisition and expression of contextual fear (Maren and Fanselow, 1995). In 
recent years, pharmacological research has revealed that metabotropic glutamate (mGlu) 
receptors may also play a role in the regulation of stress and anxiety (Palucha and Pile, 
2007). Group II metabotropic glutamate (mGlu II) receptors, which are expressed in the 
BA (Ohishi et al., 1993; Ohishi et al., 1993), have been proposed to serve as 
autoreceptors that suppress glutamate release when activated and they have been 
implicated in the modulation of synaptic transmission (Wright et al., 2001). It has also 
been found that systemic injection of mGlu II receptor agonists or antagonists can alter 
sleep (Feinberg et al., 2002; Feinberg et al., 2005). Therefore, in this study, we 
manipulated mGlu II receptors in the BA in order to investigate their potential role in 
regulating sleep and in mediating the effects of stress on sleep. 
In the following sections, we provide background information for major components 
of our studies. First, we introduce glutamate as a major excitatory neurotransmitter in the 
brain and how it may function through specific glutamate receptors including ionotropic 
(iGlu) and mGlu receptors. Specifically, we focus on mGlu II receptors that are expressed 
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in the amygdala, an important brain area involved in the regulation of emotion. We also 
provide background information for fear conditioning and fear extinction. 
1. Glutamate is an Excitatory Neurotransmitter 
Glutamate is the major excitatory neurotransmitter in the brain, and it is reported to 
be released in over half of all brain synapses (Monaghan et al., 1989). Due to the 
existence of the blood-brain barrier (endothelial cells of blood vessels in the brain which 
restrict the diffusion of large molecules from blood into the brain) glutamate is poorly 
transported from blood to cerebrospinal fluid. Therefore, brain glutamate must be 
synthesized from neurons in local areas (Cooper, 2003). In fact, in nerve terminals, 
glutamate is synthesized from two major sources: from glucose via the Krebs cycle and 
transamination of a-oxoglutarate (Fig. 1); or from glutamine transported by glial cells and 
locally metabolized by the mitochondrial enzyme, glutaminase, into glutamate (Fig. 2). 
In nerve terminals, glutamate is packaged into synaptic vesicles. Upon the 
depolarization of a nerve terminal, synaptic vesicles containing glutamate move to the 
synaptic membrane and glutamate is released through calcium dependent exocytosis. 
Reuptake of released glutamate from the synaptic cleft is accomplished by neuronal 
(GT|n]) and glial (GT[g]) Na
+-coupled glutamate transporters. Glutamate taken by glial 
cells is converted into glutamine, which is transported into the cerebrospinal fluid and 
serves as a precursor for glutamate synthesis (Fig. 2). 
2. Glutamate is Implicated in Stress and Anxiety 
As a major excitatory neurotransmitter in the brain, glutamate is thought to play an 
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Fig. 1 - Pathway of glutamate synthesis from glucose via the Krebs cycle and 




Fig. 2 - Pathway of glutamate synthesis and utilization. Released glutamate in the 
synaptic cleft is removed by neuronal (GT[„j) and glial (GT[gj) Na
+-coupled glutamate 
transporters. In glial cells, glutamine is synthesized from glutamate by the enzyme 
glutamine synthetase and released into the cerebrospinal fluid. Neuronal terminals can 
take up glutamine and convert it into glutamate through hydrolysis by the mitochondrial 
glutaminase [From Cooper, 2003]. 
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important role in the development of stress and anxiety. Studies from various labs have 
reported that chronic immobilization stress increases glutamate release and uptake in the 
hippocampus and the prefrontal cortex (PFC) (Gilad et al., 1990; Lowy et al., 1995; 
Fontella et al., 2004). In addition, chronic immobilization stress can also increase the 
messenger RNA expression level of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptors in the hippocampus (Schwendt and Jezova, 2000). Furthermore, 
injection of the NMD A receptor antagonist, D,L-2-amino-5-phosphono valerate (APV), 
into the BLA impairs both acquisition and expression of conditioned fear in rats (Maren 
etal., 1996). 
3. Glutamate is Involved in Maintaining Arousal 
Glutamate is involved in activating and maintaining arousal. Glutamate is found in 
high concentration in brain areas involved in activating and maintaining arousal, such as 
the reticular activating system (Jones, 2005). The release of glutamate in cerebral cortex 
reaches its high peak during the cortical activation of spontaneous wakefulness or 
activation induced by the stimulation of the midbrain reticular formation (Jasper et al., 
1965). Furthermore, microdialysis studies have found enhanced glutamate release in the 
rostromedial medulla during REM (Kodama et al., 1998). In addition, glutamate 
antagonists such as ketamine have sedative effects (Mayer and Westbrook, 1987). 
4. Overview of Glutamate Receptors 
Glutamate acts through stimulation of two groups of receptors: iGlu and mGlu 
receptors. Three types of iGlu receptors have been discovered that are named based on 
their respective agonists: AMPA receptors, NMD A receptors and kainate receptors. These 
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receptors are nonselective ion channels which open and allow the passage ofNa+, K a n d 
Ca2+ when the receptors are activated by binding with glutamate. While iGlu receptors 
provide fast and massive responses for signal transduction, mGlu receptors induce slower 
responses by generating signal cascades through G proteins. mGlu receptors are a family 
of eight G-protein coupled receptors: mGlul to mGlu8 receptors. They are classified into 
three groups according to their homology and pharmacology: Group I mGlu (mGlu I) 
receptors (mGlul and mGlu5), mGlu II receptors (mGlu2 and mGlu3) and Group III 
mGlu (mGlu III) receptors (mGlu4, mGlu6, mGlu7 and mGlu8). mGlu I receptors are 
positively coupled to phospholipase C whereas mGlu II receptors and mGlu III receptors 
are negatively coupled to adenyl cyclases. mGlu receptors provide a mechanism that 
modulates the activity of glutamate at the same synapses with fewer side effects (Conn 
and Pin, 1997). Therefore, ligands of mGlu receptors can be used to manipulate 
glutamate release at the synaptic level and to investigate the role of glutamate in neuronal 
plasticity. 
All mGlu receptors are homodimers that need glutamate for their functions 
(Kunishima et al., 2000). They have similar structures that can be illustrated by the 
detailed structure of the mGlul receptor (Fig. 3). The mGlul receptor has a large 
extracellular domain which is composed of a ligand-binding region (LBR) and a 
cysteine-rich region (CR) that combines LBR with the transmembrane region (TM). The 
LBRs of the mGluRl homodimer are composed of two subdomains: LB1 and LB2. The 
LBRs of the homodimer can take either of two conformations: open or closed. Binding of 
glutamate can stabilize the closed conformation, which triggers LB2 subdomains to 
combine together and thus activate the receptor. 
OpaA-^paneeritaiatevt cjisaas-assi.i eixifcivflsiiofi 
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Fig. 3 - Structure of the mGlul receptor. The receptor has a large extracellular domain 
which is composed of a ligand-binding region (LBR) and a cysteine-rich region (CR) that 
combines LBR with the transmembrane region (7 TM). The LBRs of the mGlul 
homodimer are composed of the two subdomains LB1 and LB2. The LBRs can take 
either one of two conformations: open or closed. Binding of glutamate can stabilize the 
closed conformation, which triggers LB2 subdomains of the homodimer to combine 
together and activate the receptor. CT, carboxyl terminus; Glu, Glutamate [From Moepps 
and Fagni, 2003]. 
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As mGlu receptors may modulate glutamate release at the synaptic level, the location 
of each type of receptor may be an important issue for the role of each receptor type 
(Ottersen and Landsend, 1997). Immunostaining has revealed that mGlu I receptors 
(mGlul and mGlu5) are primarily located postsynaptically (Lujan et al., 1997) whereas 
mGlu III receptors (mGlu4, mGlu7, and mGlu8) are mainly located presynaptically 
(Shigemoto et al., 1997). mGlu II receptors (mGlu2 and mGlu3) are located 
presynaptically and postsnaptically in the synaptic cleft (Petralia et al., 1996). Electron 
microscopy has revealed that mGlu2 receptors are located primarily in presynaptic 
membranes of nerve terminals. Furthermore, they are located far away from the active 
zones (Shigemoto et al., 1997). mGlu3 receptors are also expressed in glial cells and may 
contribute to the uptake of glutamate (Mineff and Valtschanoff, 1999) (Fig. 4). 
Of these glutamate receptors, we focus on mGlu receptors, which provide slower but 
long-lasting modulatory effects on synaptic transmission that may possibly be the 
underlying mechanism for the development of anxiety. Specifically, we are interested in 
mGlu II receptors, which are positioned at the area far away from active zone and may 
only act during stressful situations that trigger released glutamate to a sufficient level to 
diffuse to and activate these receptors. 
5. mGlu II Receptors 
In recent years, much attention has been paid to mGlu II receptors, which are 
considered to be a potential drug target for the treatment of anxiety disorders (Swanson et 
al., 2005). mGlu II (mGlu2 and mGlu3) receptors are expressed in brain structures 
implicated in emotion, such as the amygdala, the hippocampus and the PFC (Tamaru et 
al., 2001; Wright et al., 2001). Immunological staining has revealed that mGlu II 
10 
Fig. 4 - Localization of mGlu receptors at a theoretical synapse in the central nervous 
system. mGlu I receptors (mGlul and mGlu5) are primarily located postsynaptically in 
synapses whereas mGlu III receptors (mGlu4, mGlu7, and mGlu8) are mainly located 
presynaptically. mGlu II receptors (mGlu2 and mGlu3) are located presynaptically and 
postsynaptically in the synaptic cleft. Furthermore, they are located far away from the 
active zones. There are only mGlu7 receptors located in the active zones of the 
presynaptic terminal [From Cartmell and Schoepp, 2000]. 
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receptors are mainly located in presynaptic terminals (Shigemoto et al , 1997). mGlu II 
receptors are negatively coupled with adenylyl cyclases and the activation of mGlu II 
receptors will inhibit forskolin-stimulated cyclic AMP formation (Conn and Pin, 1997). 
Although the function of mGlu3 receptors is still under investigation, it is proposed that 
mGlu2 receptors serve as glutamate autoreceptors and are responsible for decreasing 
glutamate release level (Fig. 5). Under conditions of high glutamate release, mGlu2 
receptors will be activated and thus generate an inhibitory effect on glutamate release 
(Yokoi et al., 1996; Scanziani et al., 1997). The reduction of glutamate release may 
provide a mechanism for the anxiolytic-like effects of mGlu II receptor agonists. 
6. mGlu II Receptor Agonists: LY354740 (LY35) and LY379268 (LY37) 
mGlu II receptor agonists include LY35 and LY37, which show low nanomolar 
affinity for both receptor subtypes and are systemically active (Palucha and Pile, 2007). 
LY35 has been shown to have significant anxiolytic-like potentials in several models of 
anxiety. For example, oral administration of LY35 induces a dose-dependent reduction of 
forced swimming in rats (Helton et al., 1998). LY35 also increases open-arm activity in 
the elevated plus maze in mice (Monn et al., 1997). Intraperitoneal injection of LY35 
significantly reduces lactate-induced panic-like responses in panic-prone rats (Shekhar 
and Keim, 2000). The anxiolytic effect of LY35 has also been confirmed in humans. 
Administration of LY35 decreases fear-potentiated startle in healthy volunteers (Grillon 
et al., 2003). The mechanism underlying the anxiolytic effect of LY35 may rely on its 
stimulation of presynaptic mGlu2/3 receptors that inhibit glutamate release (Imre, 2007). 
LY37 is a derivative of LY35, and is considered to be an even more potent and selective 
agonist than LY35. In vivo microdialysis has been used to assess the ability of LY37 (10 
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Low stimulation High stimulation 
Fig. 5 - Proposed theory that mGlu2 receptors serve as autoreceptors of glutamate release. 
Under normal conditions, glutamate does not reach a level sufficient for diffusing from 
the release site to activate mGlu2 receptors located far away from the active zone. 
However, under stress, released glutamate may reach such a high level that it can diffuse 
to perisynaptic sites and activate mGlu2 receptors and hence induce inhibition of 
glutamate release [From Cartmell and Schoepp, 2000]. 
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mg/kg) to reach receptor active level in the PFC in rats. It was found that LY37 reaches 
levels of 600-800 nM in the extracellular fluid of the brain within 1 hour, and then 
declines over the next 5 hours to a level less than 30 nM (Imre, 2007). These data suggest 
that, with systemic administration, LY37 can reach brain structures such as the PFC and 
can activate mGlu II receptors for more than 6 hours. Compared with LY35, fewer studies 
have evaluated the effects of LY37 on anxiety and stress. However, evidence suggests 
that LY37 has anxiolytic effects. Systemic administration of LY37 attenuates the increase 
of norepinephrine in the PFC in rats exposed to an elevated platform (Lorrain et al., 
2005). LY37 also impacts sleep: systemic administration of LY37 in rats generates a 
dose-dependent suppression of both REM and fast EEG activity during NREM (Feinberg 
et al., 2002). 
7. mGlu II Receptor Antagonist: LY341495 (LY34) 
LY34 is a nanomolar potent antagonist of mGlu II receptors and can reverse 
agonist-induced inhibition of forskolin-stimulated cAMP formation at mGlu II receptors 
(Kingston et al., 1998). mGlu II receptors are negatively coupled to inhibitory G protein 
(Gj) and activation of these receptors can inhibit the production of cAMP. These data 
suggest that LY34 can block the function of mGlu II receptors as revealed by cAMP 
production. For example, low doses (0.3 mg/kg, ip) of LY34 can block the anxiolytic 
effects of the agonist LY35 in the elevated plus maze (O'Neill et al., 2003). These data 
confirm that LY34 is a specific mGlu II antagonist. It has been reported that systemic 
administration of LY34 enhances mouse anxiety during the elevated plus maze test 
(Linden et al., 2005). Furthermore, LY34 induces enhancement of widespread c-Fos 
expression in the brain (Linden et al., 2005). LY34 can also alter sleep. Administration of 
14 
LY34 increases arousal and suppresses REM and NREM in rats (Feinberg et al., 2005). 
8. The Amygdala 
The amygdala is an almond-like mass of gray matter located in the medial temporal 
lobes of various mammals, including human and rodents. The amygdala is structurally 
composed of multiple, distinct nuclei which have enriched internuclei and intranuclei 
connections. These nuclei are classified into three major groups: (a) the BLA group, 
composed of the LA, the BA and the AB, has extensive connections with the cerebral 
cortex including the orbital and the medial prefrontal cortex (mPFC); (b) the medial 
group has connections with the olfactory bulb and the olfactory cortex; (c) the central and 
anterior group has connections with the brainstem, the hypothalamus and visceral sensory 
structures (Fig. 6). Therefore, the amygdala connects cortical regions that are responsible 
for sensory information processing with hypothalamic and brainstem regions that are 
involved in the regulation of emotional behavior and sleep (Sah et al., 2003). 
9. The Amygdala Is Implicated in the Regulation of Stress and Sleep 
The amygdala has a critical role in conditioned fear and anxiety. In humans 
stimulation of the amygdala generates anxiety-like responses (Feindel and Penfield, 
1954), while lesions of the amygdala attenuate anxiety responses (Narabayashi et al., 
1963). Animal studies also indicate a primary role of the amygdala in fear and anxiety 
(Davis, 2000). The BA is particularly associated with fear and anxiety. Chemical and 
electrical stimulations of the BA generate anxiety-like responses (Gelsema et al., 1987; al 
Maskati and Zbrozyna, 1989). Moreover, the BA contains a high concentration of 
benzodiazepine receptors (File, 2000). Microinjection of benzodiazepine derivative, 
to 
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Fig. 6 - An illustration of the amygdala region in coronal sections. Left panel: a 
Nissl-stained hemisection of a rat brain. Middle panel: the region containing the 
basolateral complex (BLA) and the central nucleus (CNA). Right panel: nuclei of the 
lateral (LA), the basal (B), the accessory basal (AB) nucleus and the CNA. CeL: the 
lateral nuclei of the CNA; CeM: the medial nuclei of the CNA [From Sah et al, 2003]. 
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midazolam, into the BA elicits anxiolytic effects in rats in the water lick conflict test 
(Scheel-Kruger and Petersen, 1982). These data suggest that the BA may play an 
important role in regulating anxiety responses. 
The amygdala is also implicated in the regulation of sleep. The amygdala receives 
various sensory inputs into the LA and the BA. These nuclei in turn send efferent 
projections to the CNA, which projects to structures involved in the regulation of sleep, 
such as the brainstem, the basal forebrain and the preoptic nucleus of the hypothalamus. 
Evidence shows that the amygdala can modulate sleep, especially REM. For example, 
electrical stimulation of the amygdala increases REM (Smith and Miskiman, 1975). 
However, most of this work focuses on pharmacological manipulations targeting the 
CNA. For example, microinjection of the cholinergic agonist, carbachol, into the CNA 
significantly decreases total REM and electroencephalogram (EEG) power in the 5.5-10 
Hz band during REM without significantly altering NREM in rats (Sanford et al., 2006). 
Microinjection of prolactin into the CNA decreases NREM (Sanford et al., 1998). 
Microinjections of muscimol, a GABAA agonist, into the CNA induces selective 
decreases in total REM and number of REM episodes without significant changes in 
NREM or wakefulness whereas microinjections of bicuculline, a GABAA antagonist, into 
the CNA produces significant increases in REM (Sanford et al., 2002). These data 
suggest that the amygdala has an important role in the regulation of sleep. 
In contrast to the inhibitory role of GABAergic system, glutamatergic neurons 
constitute the major excitatory system in the amygdala. In this study, we investigated the 
possible role of mGlu II receptors in the BA for the regulation of stress and sleep. 
10. Fear Conditioning 
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Fear conditioning is a powerful classical paradigm that is used for study of fear and 
anxiety. During training in contextual fear conditioning, animals make associations 
between an aversive, fear-inducing stimulus, usually footshock, and the environment in 
which it is received. Afterwards, the animals exhibit fear responses when they experience 
the context alone. This is defined as contextual fear. Both the hippocampus and the BA 
are essential, as damage to these areas impairs contextual fear (Maren and Fanselow, 
1995; Maren et al., 1997). The hippocampus has projections to the BA and it is proposed 
that information regarding environmental context may be processed in a circuit from the 
hippocampus to the BA and the AB where an association may be formed between 
conditioned (CS) and unconditioned (US) stimuli (LeDoux, 2000). The BA and the AB in 
turn project to the CNA, which projects to the brainstem areas that control the expression 
of fear responses (Davis and Whalen, 2001). The CNA has direct projections to the 
nucleus of the solitary tract (NTS) and the dorsal motor nucleus of the vagus (DMN), 
which influence cardiovascular responses. The CNA also sends projections to the 
periaqueductal gray area which regulates freezing responses (defined as the absence of 
body movement except for respiration), an index of fear memory. 
Many studies have explored the role of the CNA in fear conditioning using 
techniques including electrical or chemical lesion, electrical stimulation and local 
infusion of various drugs. However, these methods may influence projections that go 
through the CNA. As shown in Fig. 7, biotinylated dextran amine (BDA), an anterograde 
tracer, was infused into the BA and the brain was sectioned to study labeled terminals. 
Many fibers were stained in the CNA, while many other fibers were found to 
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Fig. 7 - Projections of the basolateral nucleus (BL) of the amygdala revealed by 
biotinylated dextran amine (BDA) staining. CM: the medial nuclei of the central nucleus 
of the amygdala (CNA); CL: the lateral nuclei of the CNA; BLa: the anterior part of the 
BL; BLp: the posterior part of the BL; BNSTal: the anterior part of the bed nucleus of the 
stria terminalis (BNST); BNSTpl: the posterior part of the BNST [From Davis and 
Whalen,2001]. 
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pass through the CNA from the BA and to reach the bed nucleus of the stria terminalis 
(BNST). Therefore, electrical activation or lesions of the CNA may affect projections 
from the BA. In addition, the BNST also has many projections to the hypothalamus and 
the brain stem; thus, the BA may have the ability to activate the same targets through the 
BNST as it does through the CNA (Davis and Whalen, 2001). 
Therefore, it is likely that the BA has an impact on the regulation of fear responses. 
Since the major neurons in the BA are pyramidal cells that use glutamate as a 
neurotransmitter (Sah et al., 2003), we expect glutamate in the BA should play a role in 
fear conditioning. As mGlu II receptors are expressed in the BA, we used their antagonist, 
LY34, to manipulate mGlu II receptor function to determine if mGlu II receptors play a 
role in fear conditioning. 
11. Fear Extinction 
After conditioned fear is established, repeatedly presenting the shock context without 
aversive consequences will typically result in the context losing the ability to induce fear 
responses. This process is defined as fear extinction (Quirk and Mueller, 2008) (Fig. 8). 
Research has explored the neuronal mechanism underlying the acquisition and 
consolidation of fear memory. It has been proposed that acquisition and storage of 
information may rely on circuits which transmit both CS (such as the context) and US 
(such as footshock) information to the BA. Expression of conditioned fear depends on the 
pathway that transmits information regarding the CS to the BA and the CNA (Davis and 
Whalen, 2001). Interestingly, fear extinction is considered as new learning that the CS is 

















Fig. 8 - Illustration of fear extinction learning. During fear extinction, acquisition means a 
decrease in conditioned responses to the presentation of the conditioned stimulus. 
Consolidation is a process during which a long-term extinction memory is formed. 
Retrieval of extinction happens when the subject encounters the conditioned stimulus at a 
later time [From Quirk and Mueller, 2008]. 
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the amygdala may be involved in fear extinction (Quirk et al., 2000). Lesion studies have 
revealed that the mPFC is essential for the retrieval of extinction. The infralimbic neurons 
of mPFC (IL) fire only when rats retrieved extinction on the day following extinction 
training (Milad and Quirk, 2002). The IL sends extensive excitatory projections into the 
LA and the intercalated cell masses (ITC), while the prelimbic neurons of mPFC (PL) 
send heavy stimulatory inputs into the BA (McDonald et al., 1996). The BA has been 
found to send back projections to the PL, which projects to the IL (Shinonaga et al., 
1994). Interestingly, stimulation of the IL induced neuronal activity in the LA whereas 
stimulation of the PL induced neuronal activity in the BA (Rosenkranz and Grace, 2001). 
Considering that projections from the mPFC to the amygdala are mainly excitatory 
(Smith et al., 2000), the inhibitory effects of the mPFC on the amygdala may be 
attributed to the enrollment of inhibitory interneurons in the amygdala (Rosenkranz and 
Grace, 2001; Quirk and Gehlert, 2003). These data suggest that the BA may be an 
essential site for fear extinction. 
In summary, stressors and contextual reminders of stressors can generate significant 
changes in behavior and sleep. The amygdala plays an important role in the regulation of 
fear and anxiety. It has also been found to play a role in regulating sleep. Activation of 
the CNA has been found to facilitate REM generation and the inactivation of the CNA 
impedes REM generation. However, the role of the BA in regulating sleep has received 
less attention. 
Moreover, the BA is also involved in the regulation of fear extinction learning. In 
addition, mGlu II receptors are expressed in the BA and may provide a pathway for 
manipulation of glutamate release. However, the role of mGlu II receptors in regulating 
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stress-induced alterations in sleep has not been explored. In this study, we examined the 
effects of LY37 and LY34 infusions into the BA on sleep architecture and amounts. We 
also evaluated the effects of LY34 on contextual fear conditioning and fear extinction and 




GROUP II METABOTROPIC GLUTAMATE RECEPTORS IN THE 
BASAL AMYGDALA REGULATE SLEEP 
1. Introduction 
Glutamate is the major excitatory neurotransmitter in the brain and it plays an 
essential role in maintaining wakefulness (Jones, 2005). It is found in high concentration 
in neurons in the brainstem reticular activating system (Jones, 2005). In addition, the 
release of glutamate in the cerebral cortex reaches its highest peak during the cortical 
activation in spontaneous wakefulness or arousal produced by the stimulation of the 
midbrain reticular formation (Jasper et al., 1965). 
Glutamate acts through two major groups of receptors: ionotropic glutamate (iGlu) 
receptors and metabotropic glutamate (mGlu) receptors. The stimulation of iGlu receptors 
opens an ionic pathway across the postsynaptic membrane and produces a rapid synaptic 
response. In contrast, mGlu receptors stimulate cyclic AMP production and induce 
metabolic changes which are relatively slow (Cartmell and Schoepp, 2000). Eight types 
of mGlu receptors have been cloned, which are classified into three groups (I, II, III) 
according to their sequence homology, second messenger mechanism and pharmacologic 
activity (Palucha and Pile, 2007). mGlu II receptors are negatively coupled with adenylyl 
cyclases and are located mainly outside the active zone area of presynaptic terminals. 
They have been implicated in the modulation of synaptic transmission and it has been 
proposed that they serve as autoreceptors that suppress glutamate release when activated 
(Wright et al., 2001). mGlu II receptors may also affect the release of other 
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neurotransmitters, such as dopamine, y-Aminobutyric acid (GABA) and serotonin 
(Cartmell and Schoepp, 2000). 
Work at the systemic level has implicated mGlu II receptors in the regulation of sleep. 
Subcutaneous injection of the mGlu II receptor agonist, LY379268 (LY37), induces a 
dose-dependent suppression of rapid eye movement sleep (REM) following 
administration (Feinberg et al , 2002). In addition, subcutaneous injection of the mGlu II 
agonist, LY354740 (LY35), dose-dependently suppresses REM and prolongs its onset 
latency in both rats and mice, but does not alter REM in mGlu2 receptor negative mice 
(Ahnaou et al., 2009). Moreover, systemic administration of the mGlu II receptor 
antagonist, LY341495 (LY34), increases arousal by suppressing REM and non-REM 
sleep (NREM) (Feinberg et al , 2005). However, the potential neural site(s) that mediates 
these changes in sleep has not been determined. 
mGlu II (mGlu2 and mGlu3) receptors, are expressed in the amygdala (Ohishi et al., 
1993; Ohishi et al., 1993), a limbic structure increasingly implicated in the regulation of 
arousal and sleep (Sanford et al., 1998; Deboer et al , 1999; Morrison et al., 2000; 
Sanford et al., 2002; Jha et al., 2005; Tang et al., 2005) as well as having a demonstrated 
role in emotion (Davis and Whalen, 2001). Early work demonstrates that electrical 
stimulation of the amygdala increases REM (Smith and Miskiman, 1975). The central 
nucleus of the amygdala (CNA) projects to brainstem structures involved in REM 
regulation and generation (Krettek and Price, 1978; Takeuchi et al., 1982; Petrov et al., 
1994) and most recent research has focused on its role in regulating sleep (Sanford et al., 
2002; Tang et al., 2005; Sanford et al., 2006). However, involvement of other regions of 
the amygdala in the regulation of sleep is suggested by reports that bilateral electrolytic 
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and chemical lesions of the basolateral amygdala (BLA, a complex that includes the basal 
amygdala (BA), the lateral amygdala (LA) and the accessory basal amygdala (AB)) 
increase total REM and NREM amounts in rats (Zhu et al., 1998) and that bilateral chemical 
lesions of the amygdala produce more consolidated sleep in chair-restrained Rhesus 
monkeys (Benca et al., 1992). Electrical and chemical stimulation of the BLA also 
increases low voltage, high frequency activity in the cortical EEG and decreases NREM 
and total sleep time, respectively (Dringenberg and Vanderwolf, 1996; Zhu et al., 1998). 
The BA contains mGlu II receptors (Wada et al., 1998; Tamaru et al., 2001) and it 
projects to the CNA as well as to the bed nucleus of the stria terminalis (BNST) which 
has direct connections to the hypothalamus and brainstem regions (Davis and Whalen, 
2001) involved in the regulation of sleep (Sanford et al., 2002; Jones, 2005; Siegel, 2005; 
Tang et al., 2005; Sanford et al., 2006); thus, suggesting it may be an important region for 
mediating the effects of mGlu II receptors on sleep. To test this hypothesis, we 
microinjected into the BA various dosages of an mGlu II agonist (LY37) or antagonist 
(LY34) to determine whether it is a potential site for mediating their effects on sleep. 
2. Results 
2.1. Microinjection Sites 
Microinjection sites for the rats used in this study are shown in Fig. 9. Although there 
was variation in the placement, the locations indicated that each injection of drugs 
infused into the BA. Diffusion to other amygdaloid nuclei may also have been possible. 
2.2 Millimolar Dosage Range of LY37 
This study examined sleep after microinjection into the BA of three millimolar 
concentrations of LY37 (3.2 mM, 5.3 mM or 10.7 mM; 0.5 ul) or vehicle alone (VEH; 
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Fig. 9 - Line drawings of the amygdala showing placements of drug cannulae. Triangles 
indicate injection sites of 6 rats that received bilateral microinjections into the BA of 
three concentrations of LY37 (3.2 mM, 5.3 mM or 10.7 raM; 0.5 ui) and vehicle alone 
(VEH, 0.5 ul) control. Rectangles indicate injection sites of 8 rats that received bilateral 
microinjections into the BA of three concentrations of LY37 (0.1 nM, 2.0 nM or 10.0 nM; 
0.5 ul) and a vehicle (VEH, 0.5 ul) control. Circles indicate injection sites of 7 rats that 
received bilateral microinjections into the BA of three concentrations of the antagonist, 
LY34 (1 nM, 30 nM or 60 nM; 0.5 ul) and a vehicle (VEH, 0.5 ul) control. 
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distilled water, 0.5 ul). Fig. 10 presents REM (Panel A) and NREM (Panel B) plotted as 2 
h totals across the 20 h recording periods. For statistical analysis, the time spent in REM, 
NREM, total sleep and wakefulness was considered in 4 h blocks over the 20 h recording 
periods. The resulting data were analyzed by one-way repeated measures ANOVAs for 
each 4 h block. 
REM 
The ANOVAs for total REM amounts found significant drug effects for the first [F(3, 
15)=8.809, p<0.005], second [F(3, 15)=26.444, p<0.001] and third [F(3, 15)=6.174, 
pO.Ol] 4 h blocks. Compared to VEH, injection of LY37 at all three dosages 
significantly decreased REM in the first, second and third 4 h blocks (Table 1). There 
were no significant drug effects during the fourth or fifth 4 h block. 
The analyses for REM episode numbers found a significant drug effect for the first 
[F(3, 15)=11.972, p<0.001], second [F(3, 15)=19.790, p<0.001] and third [F(3, 15)=5.482, 
p<0.05] 4 h blocks. The analyses were similar for REM episode durations with 
significant drug effects found for the first [F(3, 15)=9.601, p<0.001], second [F(3, 
15)=7.169, p<0.005] and third [F(3, 15)=7.684, p<0.005] 4 h blocks. Both REM episode 
numbers and REM episode durations were significantly decreased at all dosages during 
the first and second 4 h block and at the low and medium dosage during the third 4 h 
block (Table 1). There were no significant drug effects during the fourth or fifth 4 h 
block. 
NREM, Total Sleep and Wakefulness 
The ANOVAs for total NREM amounts, total sleep and wakefulness did not reveal 
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Fig. 10 - 2 h block plots (mean±SEM) of REM (A), NREM (B), REM Episode Numbers 
(C) and Average REM Durations (D) after microinjection of the mGlu II receptor agonist 
LY37 (L: 3.2 mM, M: 5.3 mM or H: 10.7 mM; 0.5 ul) or vehicle (VEH, 0.5 ul) into the 
BA. 
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Table 1 - Time spent (min) in REM, NREM, Total Sleep, Wakefulness, REM Episode 
Numbers and REM Average Durations (mean±SEM) during 4 h blocks after 
microinjection of LY37 (Low: 3.2 mM, Medium: 5.3 mM or High: 10.7 mM; 0.5 ul) or 


































































































































































* p<0.05, ** p<0.01, *** pO.OOl; significant differences relative to VEH. Comparisons 
were conducted using Tukey tests. 
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and average NREM episode durations also did not find any significant drug effect. 
2.3. Nanomolar Dosage Range of LY37 
Because we did not observe a dosage dependent effect on REM or other sleep wake 
states after microinjections into the BA of millimolar concentrations of LY37, we ran an 
additional experiment in which a separate group of rats (n=8) received microinjections of 
LY37 at the nanomolar level (0.1 nM, 2 nM or 10 nM; 0.5 ul). Analyses were conducted 
as described above for the higher dosage range. 
REM 
During the first 4 h block, the ANOVA for total REM amounts (Fig. 11 A) found a 
significant drug effect [F(3, 21)=5.478, pO.Ol]. Compared to VEH, injection of LY37 
significantly decreased REM with injection at the high (p<0.01) and medium dosage 
(p<0.05). During the second 4 h block, the ANOVA for total REM amounts found a 
significant drug effect [F(3, 21)=3.455, p<0.05]. Compared to VEH, injection of LY37 
significantly decreased REM with injection at the high dosage (p<0.05). There were no 
significant drug effects during any other 4 h block. 
Fig. 12 presents REM average durations (Panel A) and episode numbers (Panel B) 
plotted as 4 h totals after microinjection into the BA of the various nanomolar dosages of 
LY37 or VEH. During the first 4 h block, the ANOVA for REM episode numbers found a 
significant drug effect [F(3, 21)=5.090, pO.Ol]. Compared to VEH, injection of LY37 
significantly decreased the REM episode number with injection at the high dosage 
(p<0.01). There were no significant drug effects during any other 4 h block. During the 
first 4 h block, the ANOVA for REM episode durations found a significant drug effect 
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Fig. 11 - Time spent in REM (A), NREM (B) and Total Sleep (C) plotted in 4 h blocks for 
20 h after microinjection of the mGlu II receptor agonist LY37 (L: 0.1 nM, M: 2 nM or H: 
10 nM; 0.5 ul) or vehicle (VEH, 0.5 ul) into the BA. * p<0.05, significant differences 
relative to VEH. Comparisons were conducted using Tukey tests. 
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Fig. 12 - Plots of REM and NREM parameters in 4 h blocks (mean±SEM). REM Average 
Durations (A), REM Episode Numbers (B), NREM Average Durations (C) and NREM 
Episode Numbers (D) after microinjection of LY37 (L: 0.1 nM, M: 2 nM or H: 10 nM; 
0.5 ul) or vehicle (VEH; 0.5 ul) into the BA.* p<0.05, significant differences relative to 
VEH; ++ p<0.05, significant differences between different drugs. Comparisons were 
conducted using Tukey tests. 
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[F(3, 15)=9.204, p<0.001]. Compared to VEH, injection of LY37 significantly decreased 
REM episode numbers at the high (pO.OOl) and medium (p<0.01) dosages. There was 
also a significant difference between low dosage and high dosage (p<0.05). During the 
second 4 h block, the ANOVA for REM durations found a significant drug effect [F(3, 
15)=5.413, p<0.01]. Compared to VEH, injection of LY37 significantly decreased the 
average REM duration at the high dosage (p<0.01). There were no significant drug 
effects during any other 4 h block. 
NREM, Total Sleep and Wakefulness 
As with the higher range of concentrations, the ANOVAs for NREM amounts (Fig. 
11B), total sleep amounts (Fig. 11C) and wakefulness amounts did not reveal significant 
drug effects. There were no significant drug effects in the analyses for NREM average 
durations (Fig. 12C) or episode numbers (Fig. 12D). 
2.4. Effects of LY34 on Sleep 
Fig. 13 presents REM, NREM and total sleep plotted as 2 h totals after 
microinjection into the BA of different dosages of LY34 (L: 1 nM, M: 30 nM, H:60 nM; 
0.5 ul) or VEH (0.01 M PBS, 0.5 ul) alone. The data for REM, NREM, total sleep and 
wakefulness are presented in Table 2. 
REM 
The ANOVAs for total REM amounts found significant drug effects for the first [F(3, 
18)=6.549, pO.01] and second [F(3, 18)=4.619, p<0.05] 4 h blocks. In the first 4 h block, 
injection of LY34 at the high dosage (60 nM) significantly decreased REM compared to 
that of animals injected with VEH (p<0.005) or the low dosage (p<0.05). In the second 4 





































Fig. 13 - Time spent in REM (A), NREM (B) and Total Sleep (C) plotted in 2 h blocks for 
20 h after microinjection of the mGlu II receptor antagonist LY34 (L:l nM, M: 30 nM or 
H: 60 nM; 0.5 pi) or vehicle (VEH, 0.5 ^1) into the BA. 
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Table 2 - REM, NREM, Total Sleep and Wakefulness during 4 h blocks after 
microinjection of LY34 (Low: 1 nM, Medium: 30 nM or High: 60 nM; 0.5 jal) or vehicle 














































































































* p<0.05, ** pO.Ol, *** pO.OOl; significant differences relative to VEH. Comparisons 
were conducted using Tukey tests. 
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analyses of total REM amounts did not reveal any significant drug effects in any other 4 h 
block. 
The ANOVA for REM episode numbers found a significant drug effect for the 
second 4 h block [F(3, 18)=5.484, p<0.01]. Injection of LY34 at the high dosage 
significantly decreased the REM episode number compared to VEH (p<0.01). During the 
first 4 h block, the ANOVA for average REM durations found a significant drug effect 
[F(3, 18)=4.156, p<0.05]. Injection of LY34 at the high dosage significantly decreased 
the average REM duration compared to VEH (p<0.05). There were no other significant 
effects found for REM episode numbers or REM durations. 
NREM, Total Sleep and Wakefulness 
The ANOVA for total NREM amounts found a significant drug effect in the second 4 
h block [F(3, 18)=7.355, p<0.01]. The high dosage of LY34 significantly decreased 
NREM compared to that of animals injected with vehicle (p<0.01) or low dosage 
(p<0.01). There were no significant alterations in total NREM and there were no 
significant differences in the analyses for NREM episode numbers or average NREM 
durations in any of the 4 h blocks. 
During the second 4 h block, the ANOVAs revealed significant drug effects for total 
sleep amounts [F(3, 18)=7.442, p<0.01] and total wakefulness amounts [F(3, 18)=7.442, 
p<0.01]. The high dosage of LY34 significantly decreased total sleep compared to VEH 
(p<0.01) or the low dosage of LY34 (p<0.05). Parallel changes were found in 
wakefulness in comparisons of the high dosage of LY34 to VEH (p<0.01) and the low 
dosage of LY34 (p<0.05). No other comparisons were significant. 
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3. Discussion 
Microinjection of the mGlu II agonist, LY37, into the BA at both nanomolar and 
millimolar concentrations significantly decreased REM without significantly altering 
NREM, total sleep or wakefulness. By comparison, microinjection of a high dosage of 
the specific mGlu II antagonist, LY34, into the BA significantly suppressed REM, NREM 
and total sleep and increased wakefulness. These results demonstrate that the selective 
activation of mGlu II receptors in the BA significantly and specifically suppresses REM 
in the rat whereas blocking mGlu II receptors can decrease sleep and enhance 
wakefulness. Further, these results suggest that the BA plays a role in the regulation of 
REM and NREM as well as the overall arousal level. These data are consistent with work 
of other researchers demonstrating that systemic injection of mGlu II agonists, LY37 or 
LY35, suppresses REM in a dosage-dependent manner (Feinberg et al., 2002; Ahnaou et 
al., 2009) whereas injection of LY34 increases arousal at the expense of REM and NREM 
(Feinberg et al., 2005). The present results for the first time demonstrate a specific brain 
area that could be a site where mGlu II receptors exert their effects on sleep. 
The injection of LY34 at the highest concentration (60 nM) we tested significantly 
increased wakefulness at the expense of REM, NREM and total sleep amounts. These 
results may seem surprising as microinjection of the agonist selectively decreased REM 
alone. However, the results are consistent with the theoretical role of mGlu II receptors in 
glutamate release (Cartmell and Schoepp, 2000). mGlu II receptors may serve as 
glutamate release autoreceptors in the presynaptic remote area and blockade of these 
receptors with their antagonist may contribute to the shift of glutamate release to a higher 
level which may increase the activity level in the BA. The increase of the BA activity 
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may be the reason for increasing arousal level and suppressing sleep. The observation of 
mGlu II receptors located in the perisynaptic remote area in the presynaptic terminal 
(Yokoi et al., 1996) suggests that these receptors may only work under conditions of high 
glutamate release as the released glutamate has to reach a level sufficient to travel to the 
sites of mGlu II receptors that are far away from the glutamate release site. This 
hypothesis is supported by the need for increased glutamate release for the activation of 
mGlu II receptors (Scanziani et al., 1997). It has been shown that under repetitive 
stimulation hippocampal mossy fiber synapses increase glutamate release and glutamate 
concentration in the cleft to allow glutamate to spread away from the synapse and 
therefore activate mGlu II receptors. The activated mGlu II receptors will subsequently 
suppress glutamate release. This theory gains further support by the fact that application 
of mGlu receptor antagonist a-methyl-4-carboxyphenylglycine (MCPG) enhances 
excitatory postsynaptic currents (EPSC) induced by repetitive stimuli (Scanziani et al., 
1997). 
Interestingly, mGlu II agonists may not alter the basal glutamate release suggesting 
that other mechanisms may be responsible for their selective suppression of REM. This 
suggestion is consistent with the finding that systemic or local administration of LY37 
reverses ketamine-evoked glutamate release in the medial prefrontal cortex (mPFC) but 
does not alter the basal glutamate level (Lorrain et al., 2003). Moreover, systemic or local 
administration of LY37 significantly decreases the GAB A level in the hippocampus 
(Smolders et al., 2004). Biochemistry studies further suggest that mGlu receptor agonists 
suppress GABA release from neurons in several brain areas, including the hippocampus, 
the thalamus and the accessory olfactory bulb (Anwyl, 1999; Cartmell and Schoepp, 
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2000). Therefore, we suggest that injection of LY37 did not change the basal glutamate 
release level but may have suppressed GABA release in the BA and altered the regulation 
of the CNA. 
The CNA has long been implicated in the regulation of REM. Pharmacologic 
administration of various receptor agents into the CNA has direct effects on REM 
(Sanford et al., 1995; Calvo et al, 1996). Inactivation of the CNA by muscimol, a 
GABAA agonist, decreases REM without altering NREM whereas microinjection of 
GABAA antagonist bicuculline into the CNA increases REM (Sanford et al., 2002). 
Temporal inactivation of the CNA by tetrodotoxin (TTX), a sodium channel blocker, 
significantly suppresses REM and reduces arousal as indicated by shortened NREM 
latency and decreased activity in an arousing environment (Tang et al , 2005). In addition, 
microinjection of the cholinergic agonist, carbachol, into the CNA of rats suppresses 
REM (Sanford et al., 2006). The CNA has direct projections to brainstem areas involved 
in the generation and regulation of REM, including the locus coeruleus, the laterodorsal 
tegmental nucleus and the dorsal raphe nucleus (Krettek and Price, 1978; Takeuchi et al., 
1982; Petrov et al., 1994). Considering these neuroanatomical projections and its 
connection with other amygdaloid nuclei, it is clear that the amygdala may exert its 
regulation on REM through the CNA. 
The BA appears to be involved in the amygdalar regulation of sleep. Histochemical 
tracer studies demonstrate that the BA receives various cortical and subcortical sensory 
inputs from the mPFC, the hippocampus, the midbrain and pons (Pitkanen, 2000). It has 
been demonstrated that the BA projects to the CNA and the BNST (Pitkanen, 2000). 
Various evidence indicates that the BA and CNA are essential for processing and 
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acquiring conditioned fear as lesions of either area may disrupt conditioned fear (Sarter 
and Markowitsch, 1985; Davis, 1997; Gale et al., 2004). Furthermore, the amygdala 
appears to be a critical emotional modulator of sleep (Morrison et al., 2000; Sanford et al., 
2002; Tang et al., 2005; Sanford et al., 2006). Many studies have focused on exploring 
the role of the CNA in the regulation of sleep and most techniques involved include 
electrical or chemical lesion, electrical stimulation and the local infusion of various drugs. 
However, these methods may influence projections that go through the CNA. For 
example, TTX can suppress not only neuronal cells in the CNA but also the projections 
passing through the CNA from the BA to the BNST (Davis and Whalen, 2001; Tang et al., 
2005). Therefore, activation or inactivation of the CNA may disrupt the projections from 
the BA passing through the CNA. In addition, the BNST also has many projections to the 
hypothalamus and the brain stem, thus allowing the BA to activate the same targets 
through the BNST as it does through the CNA (Davis and Whalen, 2001). 
The BA may be in a position to link input signals with outputs that regulates sleep. 
Two types of neurons are found in the BA. The first type, pyramidal neurons, comprises 
the majority of the total neuronal population. These neurons demonstrate a high level of 
immunoreactivity for glutamate and are considered glutamatergic neurons (Smith and 
Pare, 1994). Pyramidal neurons receive most afferent inputs from cortical and subcortical 
structures and send output projections (Farb et al., 1995). The second type of neurons are 
interneurons which have smaller somata compared to pyramidal neurons (McDonald, 
1992). Interneurons in the BA receive excitatory inputs from cortical, thalamic and local 
sources (Nitecka and Ben-Ari, 1987). These neurons are GABAergic and serve as local 
circuit interneurons (Pitkanen and Amaral, 1994). Stimulation of these neurons produces 
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inhibitory synaptic potentials (Rainnie et al., 1991). Interneurons send inhibitory 
projections to pyramidal neurons, which in turn send excitatory projections to intercalated 
cells (Pitkanen, 2000; Sah et al., 2003). Intercalated cells are small GABAergic cell 
bodies located between the BLA and the CNA (Millhouse, 1986). It has been found that 
intercalated cell bodies contain a population of neurons firing at much higher rates than 
cells in neighboring amygdaloid nuclei. Moreover, some individual intercalated neurons 
show state-dependent changes in firing rates (Collins and Pare, 1999). These data suggest 
that intercalated cells may modulate neurons in their projection sites through tonic 
inhibitory inputs and that this modulation may be altered by those intercalated cells that 
show state-dependent firing rates. The intercalated cell bodies are reported to receive 
excitatory inputs from the BLA and thus generate inhibitory effects in the neurons of the 
CNA (Royeretal., 1999). 
Based on the circuitry of the BA, we propose a model to explain the effects induced 
by LY37 (Fig. 14). In this model, infusion of LY37 into the BA suppresses the release of 
GABA that would, in turn, decrease interneuron activity. The pyramidal neurons in the 
BA thus receive decreased inhibitory inputs from interneurons and in turn send increased 
excitatory outputs to intercalated neurons. The result would be an increase in inhibitory 
signals to neurons in the CNA, thereby suppressing CNA activity and decreasing REM. 
This hypothesis is consistent with studies that found suppressing the CNA activity 
decreases REM (Sanford et al., 2002; Sanford et al , 2006). 
In the current study we found that mGlu II receptors in the BA play a role in the 




Fig. 14 - Model for the mechanism of the BA regulation of REM through its association 
with intercalated cells and the CNA. Interneurons in the BA send inhibitory projections to 
pyramidal cells which in turn send excitatory projections to intercalated cells. Intercalated 
cells send inhibitory projections to neurons in the CNA, which have connections with 
brainstem areas. ITC: intercalated cells. GABAergic (inhibitory) neurons are depicted 
with filled symbols; Glutamatergic (excitatory) neurons are depicted with open symbols. 
43 
the acquisition and expression of conditioned fear (Ono et al., 1995; Yaniv and 
Richter-Levin, 2000; Gale et al., 2004) as well as in the extinction of fear (Myers and 
Davis, 2007; Quirk and Mueller, 2008). mGlu II receptors have been reported to be 
involved in the development of stress and anxiety (Palucha and Pile, 2007). The 
anxiolytic property of mGlu II agonists has been supported by behavioral studies. For 
example, systemic administration of LY37 attenuates the increase of norepinephrine 
levels in the prefrontal cortex in rats exposed to an elevated platform (Lorrain et al., 
2005). Oral administration of the agonist, LY354740 (LY35), increases open-arm activity 
in the elevated plus maze in mice (Monn et al., 1997). In contrast, the antagonist, LY34 
has anxiogenic properties as intraperitoneal injections of LY34 increase plasma 
corticosterone in mice (Scaccianoce et al., 2003). These data also suggest that mGlu II 
receptors may play a role in the stress response. Furthermore, sleep and anxiety disorders 
are associated, with patients of anxiety disorders often suffering from sleep disturbances 
(Benca et al., 1992). Therefore, investigation in the role of mGlu II receptors in the 
regulation of sleep and stress may provide future approaches for the treatment of anxiety 
disorders. 
In summary, the role of mGlu II receptors in the regulation of sleep has only been 
minimally explored. The present data indicate that the BA may be a brain region where 
these receptors may exert their influence on sleep. Considering that the BA is an essential 
site in contextual fear conditioning and fear extinction, work is needed to determine if the 
BA may also play a role in the regulation of stress-induced alterations on sleep. 
4. Experimental Procedure 
4.1. Subjects 
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The subjects were 21 male Wistar rats obtained from Harlan (Indianapolis, IN). The 
rats were approximately 300 gm at the time of surgery. The rats were individually housed 
in polycarbonate cages and given ad lib access to food and water. The room for sleep 
recording/housing was kept on a 12:12 lightdark cycle with lights on from 7:00 AM to 
19:00 PM. The room temperature was maintained at 24.5° ± 0.5°C. 
4.2. Surgery 
One week following their arrival, the rats were implanted with skull screw electrodes 
for recording the electroencephalogram (EEG) and with stainless steel wire electrodes 
sutured into the nuchal muscles for recording the electromyogram (EMG). Leads from 
the implanted electrodes were routed to a 9-pin miniature plug attached to the skull. 
Guide cannulae (26 gauge) for microinjections were bilaterally implanted to introduce the 
tip of the injection cannulae into the BA (AP=-2.6, DV=8.0, ML= ±4.8 mm (Paxinos G, 
1997)). All surgeries were conducted under aseptic conditions. The rats were anesthetized 
with isoflurane (5% induction; 2% maintenance). Ibuprofen (15 mg/kg) was available in 
water 24 h before surgery and 3 days after surgery to alleviate pain. All procedures were 
conducted in accordance with the National Institutes of Health Guide for the Care and 
Use of Experimental Animals and were approved by Eastern Virginia Medical School's 
Animal Care and Use Committee (Protocol #07-005). 
4.3. Drug Preparation 
Both the agonist (LY37) and antagonist (LY34) were purchased from Tocris 
Bioscience (Ellisville, MO). Immediately prior to the microinjection, LY37 was dissolved 
in distilled water which served as vehicle. LY34 was dissolved in 0.01 M phosphate 
buffered saline (PBS) which served as vehicle. 
45 
4.4. Microinjection Procedures 
After surgery, the rats were allowed 14 days for recovery. Then they were habituated 
to the microinjection procedures for two days. After each habituation handling session, 
the rats were connected to cables for 20 h sleep recording. 
After habituation, 6 rats received bilateral microinjections into the BA of three 
concentrations of LY37 (3.2 mM, 5.3 mM or 10.7 mM; 0.5 ul) or vehicle alone (0.5 ul) 
control. In experiments with LY37 administrated at nanomolar levels, 8 rats received 
bilateral microinjections into the BA of three concentrations of LY37 (0.1 nM, 2.0 nM or 
10.0 nM; 0.5 ul) or a vehicle (0.5 ul) control. Similarly, 7 rats received bilateral 
microinjections into the BA of three concentrations of the antagonist, LY34 (1 nM, 30 
nM or 60 nM; 0.5 ul) or a vehicle (0.5 ul) control. For each drug, microinjections were 
administrated in a counterbalanced order at 5-day intervals. Following each 
microinjection, the rats were returned to their home cages and connected to recording 
cables. Sleep was then recorded for 20 hours. 
For microinjections, cannulae (33 ga.), which projected 1.0 mm beyond the tip of the 
guide cannulae, were secured in place within the guide cannulae. The injection cannulae 
were connected to lengths of polyethylene tubing that in turn were connected to 5.0 ul 
Hamilton syringes. The injection cannulae and tubing had been pre-filled with the 
solution to be injected. Solutions in a volume of 0.5 ul were slowly infused over 3 min, 
with the cannulae left in place 1 min prior to the start and 1 min after the completion of 
the microinjection. 
4.5. Sleep Recording 
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Sleep recording was performed with rats in their home cages. A lightweight, shielded 
cable was connected to a plug in the rats' head. The cable was connected to a swivel that 
allowed free movement for the rats within their cages. EEG and EMG signals were 
processed by a Grass Model 12 polygraph equipped with model 12A5 amplifier and 
routed to an A/D board (Eagle PC30) housed in a Pentium class PC. The signal were 
digitized at 128 HZ and collected in 10-second epochs using a custom sleep data 
collection program. 
4.6. Determination of Sleep 
The EEG and EMG records were visually scored by a trained observer to determine 
wakefulness, NREM and REM in 10-second epochs (Sanford et al., 2002). Wakefulness 
was determined by the presence of low-voltage, fast EEG; high-amplitude, tonic EMG 
levels; and phasic EMG bursts that could be associated with gross body movements. 
NREM was scored by the presence of spindles interspersed with slow waves, lower 
muscle tone, and no gross body movements. REM was determined by the presence of 
low-voltage, fast EEG, theta rhythm, and muscle atonia. 
4.7. Data Analysis 
Statistical analyses were conducted using SigmaStat (SPSS, Inc., Chicago, Illinois). 
One-way repeated measures ANOVAs across drug treatment were used to analyze sleep 
alteration in 4 h blocks. The Tukey tests were used when all pairwise comparisons among 
means were made across drug treatments. 
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CHAPTER III 
MICROINJECTION OF GROUP II METABOTROPIC GLUTAMATE 
RECEPTOR ANTAGONIST, LY341495, INTO THE BASAL AMYGDALA 
FACILITATES FEAR EXTINCTION AND ATTENUATES FEAR-INDUCED 
ALTERATIONS IN SLEEP 
1. Introduction 
In contextual fear conditioning, animals make associations between an aversive, 
fear-inducing stimulus, usually footshock, and the environment in which it is received. 
Afterwards, the animals exhibit fear responses when they experience the context alone. In 
addition to well established behavioral signs of fear (e.g., freezing defined as no 
movement except for respiration (Blanchard and Blanchard, 1969; Doyere et al , 2000)), 
sleep in the period after contextual fear is characterized by significant reductions in rapid 
eye movement sleep (REM) (Sanford et al., 2003; Tang et al., 2005). Repeated or 
prolonged exposure to fearful contexts without footshock will result in fear extinction in 
which the context no longer elicits behavioral fear responses (Myers and Davis, 2007; 
Quirk and Mueller, 2008). Sleep also normalizes after contextual fear extinction 
(Wellman et al., 2008). 
The amygdala is essential in the regulation and expression of emotion and fear. 
Lesions of the basolateral complex of the amygdala (BLA) disrupt the acquisition and 
expression of fear conditioning (Maren et al., 1996). However, the BLA is not a unitary 
structure as it includes the lateral amygdala (LA), the basal amygdala (BA) and the 
accessory basal (AB) nuclei. Of these subregions of the BLA, the LA appears to be 
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primarily associated with auditory fear conditioning (LeDoux et al., 1990) whereas the 
BA is associated with contextual cues in fear conditioning (Fanselow and LeDoux, 1999; 
LeDoux, 2000). The BA receives projections from the ventral hippocampus (Canteras and 
Swanson, 1992), and electrolytic lesions in either site impairs conditioned fear to 
contextual cues (Maren and Fanselow, 1995). Neurons in the BA are found to respond to 
conditioned and unconditioned stimuli, suggesting that the BA is the location where 
conditioned stimuli (CS) and unconditioned stimuli (US) are associated (Ono et al., 1995; 
Toyomitsu et al., 2002). In addition, ibotenate lesions of the BA disrupt contextual fear 
conditioning but not auditory fear conditioning (Onishi BK, 2009). The BA is also 
implicated in fear extinction. Inhibition of N-methyl-D-aspartate (NMDA) receptors in 
the BA disrupts the expression and extinction of conditioned fear to contextual stimuli 
(Lee and Kim, 1998). 
The BA receives various sensory inputs and projects to the central nucleus of 
amygdala (CNA), which in turn projects to sleep related structures such as the brainstem, 
the basal forebrain and the preoptic nucleus of the hypothalamus (Pitkanen, 2000; Davis 
and Whalen, 2001). Research on the role of the amygdala and sleep has typically focused 
on the CNA. For example, microinjections into the CNA of GABAergic (Sanford et al., 
2002), cholinergic (Sanford et al., 2006) and serotonergic (Sanford et al., 1995) agents 
significantly alter REM in rats. Indeed, most data indicate that the CNA plays an 
important role in the regulation of REM. In contrast, few studies have examined the 
potential role of the BA in the regulation of sleep. 
In the BA, pyramidal neurons are the major neurons, which use glutamate as the 
primary neurotransmitter (Washburn and Moises, 1992). Group II metabotropic glutamate 
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(mGlu II) receptors, which are expressed in the BA, serve as autoreceptors for glutamate 
release and may play a modulatory role for determining glutamate level in the BA 
(Petralia et al., 1996). Evidence shows that systemic injection of the mGlu II receptor 
antagonist, LY341495 (LY34), induces significant c-Fos expression, a marker of neural 
activity, all over the brain (Linden et al., 2005), which suggests that blockage of mGlu II 
receptors may contribute to increased neuronal activity. Our previous studies have 
revealed that the microinjection of LY34 into the BA significantly increases wakefulness 
at the expense of REM, NREM and total sleep amounts. These data indicate that injection 
of LY34 into the BA may change the activity of the BA as well as subsequent sleep. 
The involvement of the BA in conditioned fear and fear extinction also suggests a 
possible role of mGlu II receptors in the BA in fear extinction and its effects on sleep. 
Therefore, the purpose of this study was to investigate the role of mGlu II receptors in the 
BA in fear extinction and to determine whether any potential alteration in extinction was 
related to subsequent changes in sleep. Rats were trained in contextual fear using a 
footshock stressor and received LY34 (30 nM) or vehicle (VEH, 0.01 M PBS) prior to 
re-exposure to the fearful context alone on the following day (extinction training day). 
The rats were also tested in the context on the second day after shock training (test day) 
and at the ninth day after shock training (retest day). Freezing was examined as a measure 
of fear memory and sleep was recorded for 20 h after each session. 
2. Results 
2.1. Microinjection Sites 
Microinjection sites for each rat used in the study are shown in Fig. 15. Although 
Fig. 15 - Line drawings of the amygdala showing placements of drug cannulae. 
Rectangles indicate injection sites of 8 rats that received bilateral microinjections into the 
BA of LY34 at 30 nM (0.5 ul). Circles indicate injection sites of 7 rats that received 
bilateral microinjections into the BA of vehicle (0.5 ul) control. 
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there was variation in the placement around the BA, the locations indicated that each 
injection of drugs was infused into the BA. Diffusion to other amygdaloid nuclei may 
also have been possible. 
2.2. Freezing 
The percentage of time spent in freezing (FT%) was calculated for specific periods 
during the shock training day, the extinction training day and the test and retest days. For 
shock training, the FT% data were divided into 3 periods: 5 min pre-shock period, 20 min 
shock training period and 5 min post-shock period. For the 1 h extinction training session, 
the data were divided into four blocks: PI (1st 15 min), P2 (2nd 15 min), P3 (3rd 15 min) 
and P4 (4th 15 min) periods. The 30 min test and retest sessions were divided into two 15 
min periods: PI and P2. FT% was averaged for each minute during each time block. 
Freezing in the pre-shock period was used as a baseline to determine whether the animals 
showed significant fear responses during subsequent periods. 
Freezing on Shock Training Day (Fie. 16A) 
The ANOVA for freezing across periods and conditions found a significant main 
effect for the assessment period [F(2, 2)=59.595, pO.OOl]. There were no significant 
differences in the two groups prior to being treated with VEH or LY34. Both groups of 
animals showed minimal freezing during the pre-shock period on the first day whereas 
FT% was significantly increased during the shock training session (p < 0.001) and the 
post-shock session (p O.001) when compared to the pre-shock session. 
Freezing during Extinction (Fie. 16B) 
The ANOVA for freezing found a significant main effect for the drug [F(l, 4)=7.892, 
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Fig. 16 - Average percentage of time spent in freezing (FT%) plotted for each 
measurement period. (A) FT% during pre-shock, shock and post-shock periods of vehicle 
injected animals (VEH) or LY34 injected animals (LY34) on the shock training day. (B) 
FT% during the PI (1st 15 min), P2 (2nd 15 min), P3 (3rd 15 min) and P4 (4* 15 min) 
periods of extinction training. (C) and (D) FT% in the PI (1st 15 min) and P2 (2nd 15 min) 
periods during test and retest session. * p<0.05, differences relative to pre-shock period 
of FT%; ++ p<0.05, differences between the VEH group and the LY34 group. 
Comparisons were conducted using Tukey tests. 
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p<0.001] as well as a significant interaction of drug treatment X assessment period [F(4, 
40)=58.985, PO.OOl]. During extinction training, VEH treated animals exhibited 
significantly increased FT% in PI (pO.OOl), P2 (pO.OOl), P3 (p<0.001) and P4 
(p<0.001) compared to pre-shock. VEH treated animals also exhibited increased FT% in 
P2 (p<0.001) compared to PI, decreased FT% in P3 compared to P2 (p<0.001) and 
decreased FT% in P4 compared to P3 (p<0.001). 
Compared to pre-shock, LY34 treated animals showed significantly increased FT% 
in PI (pO.OOl), P2 (pO.OOl) and P3 (pO.Ol) whereas in P4 (p=0.436) FT% did not 
significantly differ from pre-shock levels. FT% was also significantly higher in PI than in 
P2 (pO.OOl), P3 (pO.OOl) and P4 (pO.OOl) and was also significantly higher in P2 
than in P4 (pO.OOl). 
Compared to VEH treated rats, LY34 treated rats showed significantly greater FT% 
in PI (pO.OOl) and significantly decreased FT% during P2 (pO.OOl), P3 (pO.OOl) and 
P4 (pO.Ol). 
Freezing on Test Day (Fig. 16C) 
The ANOVA for freezing found a significant main effect for the drug treatment [F(l, 
2)=23.731, pO.OOl] and a significant main effect for the assessment period [F(2, 
2)=26.010, pO.OOl] as well as a significant interaction of drug treatment X assessment 
period [F(2, 24)=11.277, pO.OOl]. In VEH treated rats, FT% was significantly higher 
compared to pre-shock during PI (pO.Ol) and P2 (pO.OOl). In LY34 treated rats, FT% 
did not significantly differ compared to pre-shock during either PI or P2. 
VEH and LY34 treated rats did not significantly differ in FT% during PI (p=0.069); 
however, LY34 injected animals showed significantly lower FT% during P2 (pO.OOl). 
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Freezing on Retest Day (Fis. 16D) 
The ANOVA for freezing found a significant main effect for the drug treatment [F(l, 
2)=25.589, PO.001] and a significant main effect for the assessment period [F(2, 
2)=165.729, PO.001] as well as a significant interaction of drug treatment X assessment 
period [F(2, 24)= 11.281, pO.OOl]. 
In both VEH and LY34 injected animals, FT% during PI and P2 was significantly 
higher than pre-shock (p<0.001). There was a significant difference between groups 
during either PI (p<0.05) or P2 (pO.OOl). 
2.3. Sleep following each Training Session 
REM, NREM and total sleep were analyzed in 4 h blocks for the 20 h recording 
periods during each phase of the experiment (shock training day, extinction day, test day 
and retest day). This resulted in five 4 h blocks: Bl and B2 in the light period and B3, B4 
and B5 in the dark period. The ANOVA analysis for baseline sleep did not find significant 
differences between the two groups of animals. Therefore, the combined baseline data 
were used to determine whether the drug or treatments had effects on subsequent sleep. 
All the data were analyzed by two-way ANOVA. 
Sleep on the Shock Training Day 
The ANOVA for total REM amounts across treatments and time blocks found a 
significant main effect for the treatment [F(2, 4)=20.296, pO.OOl] and a significant 
interaction for treatment X time block [F(4, 8)=2.505, pO.05]. Compared to the baseline, 
shock training significantly suppressed REM in both groups during the first and second 4 
h blocks (Fig. 17A , pO.01). Shock training did not produce any significant change in 
REM between the two groups of animals (Fig. 17 A) in any of the five 4 h blocks. 
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The ANOVA for total NREM amounts across treatments and time blocks found a 
significant main effect for the treatment [F(2, 4)=5.444, p<0.01] and a significant 
interaction for treatment X time block [F(4, 8)=3.747, pO.OOl]. Shock training 
significantly suppressed NREM in both groups during the first 4 h block (Fig. 18A, 
p<0.001). However, VEH treated animals and LY34 treated animals showed no 
significant difference in NREM (Fig. 18 A) in any of the five 4 h blocks. 
The ANOVA for total sleep amounts across treatments and time blocks found a 
significant main effect for the treatment [F(2, 4)=7.989, pO.OOl] and a significant 
interaction of treatment X time block [F(4, 8)=3.952, pO.OOl]. Shock training 
significantly suppressed total sleep in both groups during the first 4 h block (Fig. 19A, 
p<0.001). However, VEH treated animals and LY34 treated animals showed no 
significant difference in total sleep (Fig. 19A) in any of the five 4 h blocks. 
Table 3 presents REM episode numbers and average durations during the 4 h blocks 
following each treatment. The ANOVA for REM episode numbers during the shock 
training day found a significant main effect for shock [F(2, 4)=52.602, pO.OOl] and a 
significant interaction of treatment X time block [F(4, 8)=12.117, pO.OOl]. Shock 
significantly suppressed REM episode numbers for both groups during the first and 
second 4 h blocks (Table 3, pO.OOl). Also the ANOVA for REM average durations found 
a significant main effect for shock [F(2, 4)=12.740, pO.OOl] and a significant interaction 
of treatment X time block [F(4, 8)=2.242, pO.05]. Shock significantly suppressed REM 
average durations for both groups during the first and second 4 h blocks (Table 3, 
PO.01). 
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A Shock B Extinction 
Fig. 17 - Time spent in REM plotted in 4 h blocks for 20 h after Shock training (A), 
Extinction training (B), Testing (C) and Retesting (D). * p<0.05, significant differences 
relative to the baseline (BAS); ++ p<0.05, significant differences between the VEH group 
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B2 B3 B4 B2 B3 B4 B5 
Fig. 19 - Time spent in Total Sleep plotted in 4 h blocks for 20 h after Shock training (A), 
Extinction training (B), Testing (C) and Retesting (D). * p<0.05, significant differences 
relative to the baseline (BAS). Comparisons were conducted using Tukey tests. 
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Table 3 - REM Episode Numbers and REM Average Durations (mean±SEM) during 4 h 
blocks following each treatment. 
Conditions 






































































































































* p<0.05, ** p<0.01, *** pO.OOl; significant differences compared to the baseline. 
Comparisons were conducted using Tukey tests. 
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Sleep on the Extinction Trainins Day 
The ANOVA for total REM amounts across treatments and time blocks found a 
significant main effect for the treatment [F(2, 4)=T6.882, pO.OOl] and a significant 
interaction of treatment X time block [F(4, 8)=3.041, pO.01]. Compared to the baseline, 
there was no significant difference for the VEH group across the first and second 4 h 
blocks (Fig. 17B). In contrast, extinction significantly increased REM in the LY34 group 
compared to the VEH group in the first (p<0.05) and second 4 h block (pO.OOl) as well 
as compared to the baseline in the first 4 h block (p<0.01) and second 4 h block 
(pO.OOl). 
The ANOVA for total NREM amounts found no significant effect for the treatment 
[F(2, 4)=2.460, p=0.089]. The VEH group and the LY34 group showed no significant 
difference in NREM (Fig. 18B) in any of the five 4 h blocks. However, the ANOVA for 
total sleep amounts found a significant effect for the treatment [F(2, 4)=3.468, p<0.05]. 
There was an overall increased total sleep for the LY34 group compared to the VEH 
group (p<0.05). 
The ANOVA for REM episode numbers during the extinction training day found a 
significant main effect for the treatment [F(2, 4)=8.939, pO.OOl] and a significant 
interaction of treatment X time block [F(4, 8)=2.533, pO.05]. Extinction training 
significantly increased the REM episode number in the LY34 group during the second 4 h 
block compared to both the baseline and the VEH group (Table 3, pO.OOl). The ANOVA 
for REM average durations did not find any significant difference. 
Sleep on the Test Day 
The ANOVA for total REM amounts across treatments and time blocks found a 
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significant main effect for treatment [F(2, 4)=4.345, p<0.05] and a significant interaction 
of treatment X time block [F(4, 8)=3.285, p<0.01]. Compared to the baseline, there was 
no significant difference for the VEH group during the first and second 4 h blocks (Fig. 
17C). However, there was significantly increased REM in the LY34 group compared to 
the VEH group in the first 4 h block (p<0.001) as well as compared to the baseline in the 
same period (pO.OOl). 
The ANOVA for total NREM amounts found no significant effect for the treatment 
[F(2, 4)=2.807, p=0.064]. Similarly the ANOVA for total sleep amounts found no 
significant effect for the treatment [F(2, 4)=2.365, p=0.098]. 
The ANOVA for REM episode numbers during the test day found a significant main 
effect for the treatment [F(2, 4)=4.388, p<0.05] and a significant interaction of treatment 
X time block [F(4, 8)=5.818, pO.OOl]. The REM episode number was significantly 
increased in the LY34 group during the first 4 h blocks compared to both the baseline and 
the VEH group (Table 3, p<0.001). The ANOVA for REM average durations did not find 
any significant difference. 
Sleep on the Retest Day 
The ANOVA for total REM amounts across treatments and time blocks found no 
significant effect for the treatment [F(2, 4)=2.425, p=0.092]. The ANOVA for total 
NREM amounts found no significant effect for the treatment [F(2, 4)=0.648, p=0.525]. 
Similarly the ANOVA for total sleep amounts found no significant effect for the treatment 
[F(2,4)=0.974,p=0.380]. 
The ANOVA for REM episode numbers or average durations did not find any 
significant differences. 
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2.4. Sleep Comparisons across Training Conditions among Each Group 
We compared select sleep parameters in the light period across conditions separately 
in the VEH group and the LY34 group. Fig. 20 presents average REM (Fig. 20A, D), 
NREM (Fig. 20B, E) and total sleep (Fig. 20C, F) amounts in two 4 h blocks for the VEH 
and the LY34 group, respectively. 
Sleep Comparisons across Training Conditions in the VEH Group 
The ANOVA for total REM amounts across training found a significant effect for 
training [F(4, 24)=9.302, pO.OOl]. Compared to the baseline, shock training 
significantly suppressed REM in both 4 h blocks (p<0.01) whereas extinction training 
significantly increased REM compared to shock in both 4 h blocks (p<0.01) and 
normalized REM to the baseline level. On the test day, animals in the VEH group showed 
higher REM in the first (pO.OOl) and second (p<0.01) 4 h block compared to equivalent 
time periods on the shock training day. During the retest day, REM was also significantly 
higher in both 4 h blocks (p<0.05) than on the shock training day. 
The ANOVA for total NREM amounts across training found a significant effect for 
training [F(4, 24)=7.943, pO.OOl]. Shock training significantly suppressed NREM in the 
first 4 h block (pO.Ol), whereas NREM increased following extinction (pO.OOl), 
testing (pO.05) and retesting (pO.Ol) during the same period. The ANOVA for total 
sleep amounts across training found a significant effect for training [F(4, 24)=8.594, 
pO.OOl]. Compared to the baseline, shock training significantly suppressed total sleep in 
the first 4 h block (pO.Ol). By comparison, total sleep was increased following 
extinction (pO.OOl), test (pO.Ol) and retest (pO.Ol) sessions during the first 4 h block 





































































































































































































































































































































































































Sleep Comparisons across Trainim Conditions in the LY34 Group 
The ANOVA for total REM amounts across training found a significant effect for 
training [F(4, 28)=26.455, p<.001]. Compared to the baseline, shock training 
significantly suppressed REM in first 4 h block (pO.OOl) and second 4 h block (p<0.05). 
Extinction training significantly increased REM when compared to shock during both 4 h 
blocks (pO.OOl) and when compared to the baseline in the second 4 h block (pO.OOl). 
Following the test session, animals showed higher REM in the first (p<0.001) and second 
(p<0.001) 4 h block compared to those periods during the shock training day. Also, the 
animals showed increased REM compared to the baseline in the first 4 h block (p<0.01). 
On the retest day, REM was significantly higher in both 4 h blocks (p<0.05) compared to 
those periods on the shock training day. 
The ANOVA for total NREM amounts found a significant effect for training [F(4, 
28)=7.127, pO.OOl]. Shock training significantly suppressed NREM in the first 4 h 
block (p<0.01), whereas NREM was increased following extinction (pO.Ol) and retest 
(p<0.01) during the same period. 
The ANOVA for total sleep amounts also found a significant effect for training [F(4, 
28)=9.317, pO.OOl]. Shock training significantly suppressed total sleep in the first 4 h 
block (pO.OOl), whereas total sleep was increased during the first 4 h block following 
extinction (pO.OOl), test (pO.Ol) and retest (pO.Ol) sessions compared to the same 
period. 
3. Discussion 
The current results demonstrate that mGlu II receptors in the BA may play a role in 
regulating fear extinction. Microinjection of the mGlu II antagonist, LY34, exacerbated 
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fear responses induced by contextual environment in the early period (PI) of extinction 
training. However, rats receiving LY34 showed attenuated fear responses in the later 
periods (P2, P3 and P4), suggesting that mGlu II receptors may exert a regulatory role in 
fear responses. Also, we observed a significant increase in REM in the LY34 group 
following both extinction training and on the test day compared to the VEH group. 
However, we did not observe any significant difference in NREM or total sleep between 
the LY34 and VEH groups. These data suggest that the BA may also be involved in the 
regulation of REM. 
The level of freezing has been used as an index for measuring fear, with higher FT% 
indicating greater fear reactions (Blanchard and Blanchard, 1969; Doyere et al., 2000). In 
rodents, shock training can significantly increase FT% to a relatively high level during 
shock and post-shock periods compared to that of the pre-shock period, indicating that 
animals successfully acquired conditioned fear (Tang et al., 2005; Wellman et al., 2008). 
Contextual fear can induce an increased FT% level similar to shock. However, the level 
of FT% is typically reduced after animals are repeatedly exposed to the context without 
shock. It has been reported that rats exhibited a cessation of freezing by the end of a 
one-hour long session, which indicated that fear extinction occurred (Wellman et al , 
2008). In the current study, both groups in early periods of extinction (PI and P2) 
exhibited higher FT% compared to later periods (P3 and P4). These data are consistent 
with our previous finding that the context can induce fear responses, while extinction 
training can reduce fear responses. Interestingly, the microinjection of LY34 in the BA 
exacerbated fear responses in PI and reduced fear responses in the later periods (P2, P3 
and P4) when compared to the VEH group. Also the LY34 group exhibited lower FT% 
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compared to the VEH group during the test and retest. These data suggest that LY34 
facilitates fear extinction that reduces fear responses. 
It has been reported that mGlu II receptors are implicated in cognitive performance. 
For example, systemic injection of the agonist LY35 induces a cognitive impairment in 
which rats demonstrates a delay-dependent deficit in the delay-match or non-match task 
and impaired spatial learning in the Morris water maze. In contrast, systemic injection of 
LY34 can block the effects of LY35 in the delay-match or non-match task and increase 
spatial learning in the Morris water maze (Higgins et al., 2004; Shimazaki et al., 2007). A 
possible mechanism may be that administration of LY35 inhibits neuronal transmission in 
the perforant path inputs to both the dentate gyrus and the stratum lacunosum moleculare 
of the CA1 in the hippocampus (Kew et al., 2001). Evidence indicates that the amygdala 
can modulate cognition and learning through mediating stress effects on hippocampal 
long-term potentiation (LTP) (Kim et al., 2001). For instance, blockage of the BLA impairs 
spatial learning (Roozendaal et al., 1998); lesion of the CNA impairs attention during 
Pavlovian fear conditioning (Holland et al., 2000); and lesion of the BLA impairs in vivo 
LTP in the dentate gyrus of the hippocampus (Ikegaya et al., 1994). In addition, the 
amygdala sends projections to the hippocampus (Sah et al., 2003), through which it may 
potentially modulate hippocampal function. Therefore, we propose that microinjection of 
LY34 into the BA may modulate the activity of the amygdala and enhance cognitive 
performance and learning through the hippocampus. The enhancement of an animal's 
recognition of the contextual environment may trigger a higher fear response in the 
beginning of fear extinction, and then later facilitate fear extinction. 
The alteration of REM has often been associated with stress and fear (Sanford et al., 
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1995; Sanford et al., 2001; Jha et al., 2005; Wellman et al., 2008). Previous work in our 
lab has found that footshock induces suppression of REM without later recovery and 
fearful contexts can induce similar effects on REM in both rats and mice (Sanford et al., 
2003; Tang et al., 2005). In the current study, we found that shock training reduced REM 
in both the VEH and LY34 groups. By comparison, extinction training on the following 
day significantly increased REM. Following the test on the third day, the LY34 group 
again demonstrated significantly increased REM compared to the VEH group. 
Considering that administration of LY34 in the BA alone suppressed REM, extinction 
learning may be the reason for the increased REM in the LY34 group. These data suggest 
that injection of LY34 may facilitate the effects of extinction training, which in turn 
increases REM. 
Shock suppressed NREM in both groups while extinction training was found to 
restore it to the baseline level. We observed similar results for total sleep. These data are 
consistent with results showing that extinction training significantly increases NREM and 
total sleep compared to that following shock training one day before (Wellman et al., 
2008). 
Fear extinction has been studied for decades and is currently considered to be a 
learning process that forms new circuits that inhibit old conditioned reactions (Quirk and 
Mueller, 2008). Failure of extinction of conditioned fear may be the mechanism 
underlying persistent anxiety reactions, such as posttraumatic stress disorder (PTSD) 
(Pitman, 1997). Various evidence indicates that the mPFC and the amygdala are involved 
in fear extinction and it has been proposed that the mPFC inhibits conditioned fear 
through inhibition of CNA outputs (Quirk et al , 2003). Anatomically, the BA appears to 
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be located at a potentially crucial position for contextual fear extinction as it has 
reciprocal connections with the mPFC, the hippocampus and the CNA (Sah et al., 2003). 
Inhibition of NMDA receptors in the BA disrupts the expression and extinction of 
conditioned fear to contextual stimuli (Lee and Kim, 1998). These data suggest that the 
BA may be an essential site for fear conditioning and extinction. In the current study, 
LY34 in the BA facilitated fear extinction as indicated by changes in FT% and REM. 
These results support for a role of the BA in the regulation of fear extinction. These 
results also demonstrate for the first time that mGlu II receptors may affect fear 
extinction. 
Injection of LY34 enhances neuronal activity, as indicated by the increase of c-Fos 
expression in the brain (Linden et al., 2005; Hetzenauer et al., 2008). The BA projects to 
prelimbic (PL) neurons of the mPFC, which in turn project to the infralimbic (IL) 
neurons of the mPFC. The IL sends extensive excitatory projections to the LA and the 
intercalated cell masses (ITC). In contrast, the PL sends projections back to the BA 
(McDonald et al., 1996). This circuitry may be involved in the observed suppression of 
freezing. Extinction learning stimulates pyramidal cells in the BA, which send out 
excitatory outputs to the PL. The PL stimulates the IL which sends excitatory signals to 
the ITC, which, in turn, inhibits the CNA. The inhibition of the CNA may regulate the 
suppression of freezing (Sotres-Bayon et al., 2004). Thus, the injection of LY34 may 
increase neuronal activity in the BA, which sends out stronger excitatory stimulus to the 
PL and the IL, thus producing stronger inhibition in the CNA. This could account for the 
lower freezing level in the LY34 group compared to the VEH group. This conception is 
consistent with current literature explaining fear extinction. However, it does not explain 
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the enhancement of REM, which likely involves increased activation of the CNA 
(Sanford et al., 2002; Sanford et al., 2006). Therefore, additional work is needed to 
reconcile the mechanisms that underlie the increases of REM with those that regulate fear 
memory, as indicated by freezing. 
Conditioned fear has been linked to the development of anxiety disorders including 
PTSD (Shalev et al., 1992). The failure of fear extinction appears to be an important 
factor in PTSD (Peri et al., 2000) and extinction-based exposure therapies are widely 
used for its treatment as well as other anxiety disorders (Foa, 2006). Sleep disturbances, 
including significant alterations in REM, are common features of PTSD (Germain et al., 
2008; Sateia, 2009). However, there has been virtually no research on the neural 
processes that may underlie the relationship between fear extinction and sleep. This study 
is the first research to explore the role of mGlu II receptors in extinction learning and 
subsequent sleep. 
Also in this study, we examined the spontaneous recovery of fear following 
extinction (Fig. 20). In the short-term (test day, one day following extinction day) and 
long-term (retest day, nine days following extinction day), we did not find any 
spontaneous recovery of fear in either group as evidenced by REM, a sensitive index for 
fear (Jha et al., 2005). These data suggest that extinction training could ameliorate 
conditioned fear, which may provide approaches for the treatment of anxiety disorders, 
such as PTSD. 
In summary, the role of the B A in regulating stress and stress-induced alterations in 
sleep has been minimally studied. Our data demonstrate that the BA may exert a role in 
fear-induced alterations in sleep. LY34 applied in the BA can facilitate fear extinction, 
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which in turn induces an increase of REM and NREM. The mechanism and pathways by 
which these effects are mediated require further study. 
4. Experimental Procedure 
4.1. Subjects 
The subjects were fifteen male Wistar rats from Harlan (Indianapolis, IN) of 
approximately 300gm at the time of surgery. The rats were individually housed in 
polycarbonate cages and had ad lib access to food and water. The room for sleep 
recording/housing was kept on a 12:12 lightdark cycle with lights on from 7:00 AM to 
19:00PM. The room temperature was maintained at 24.5°C ± 0.5°C. 
4.2. Surgery 
One week following their arrival, the rats were implanted with skull screw electrodes 
placed in the skull for recording the electroencephalogram (EEG) and with stainless steel 
wire electrodes sutured into the nuchal muscle for recording the electromyogram (EMG). 
Leads from the implanted electrodes were led subcutaneously to the skull and routed to a 
9-pin miniature plug attached to the skull. Guide cannulae (26 gauge) for microinjections 
were bilaterally implanted to introduce the tip of the injection cannulae into the target 
areas at the BA (AP=-2.6, DV=8.0, ML= ±4.8 mm (Paxinos G, 1997)). All surgeries were 
conducted under aseptic conditions. The rats were anesthetized with isoflurane (5% 
induction; 2% maintenance). In addition, ibuprofen (15 mg/kg) was available in water 
24 h before surgery and 3 days after surgery to alleviate pain. All procedures were 
conducted in accordance with the National Institutes of Health Guide for the Care and 
Use of Experimental Animals and were approved by Eastern Virginia Medical School's 
Animal Care and Use Committee (Protocol #07-005). 
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4.3. Drug preparation and Microinjection Procedure: 
The mGlu II receptor antagonist, LY34, was purchased from Tocris Bioscience 
(Ellisville, MO). Immediately prior to the microinjection, LY34 was dissolved in 0.01M 
phosphate buffered saline (PBS). PBS alone was microinjected into the vehicle control 
animals. 
Microinjections were administrated immediately before the start of extinction 
training. Eight rats in the experimental group received microinjection of antagonist LY34 
(30 nM, 0.5 ul) while seven rats in the control group received microinjection of vehicle 
PBS (0.01 M, 0.5 ul). 
For microinjections, injection cannulae (33 ga.), which projected 1.0 mm beyond the 
tip of the guide cannulae, were secured in place within the guide cannulae. The injection 
cannulae were connected to lengths of polyethylene tubing that in turn were connected to 
5.0 ul Hamilton syringes. The injection cannulae and tubing had been pre-filled with the 
solution to be injected. The solutions in a volume of 0.5 ul were slowly infused over 3 
min, with the cannulae left in place 1 min prior to the start and lmin after the completion 
of the microinjection. 
4.4. Experimental Procedures 
After surgery, the rats were allowed 14 days for recovery. Then they were habituated 
to microinjection procedures for two days. After each habituation handling, the rats were 
connected to cables for 20 h sleep recording. 
After habituation, the rats were randomly assigned to one of the following two 
groups: the experimental group in which rats would be injected with LY34 (30 nM, 0.5 ul) 
immediately before extinction training and the control group in which rats would be 
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injected with vehicle (0.01 M PBS, 0.5 jal) immediately before extinction training. 
Baseline sleep was recorded for 20 hours. Two days after baseline recording, the rats 
received shock-training. Individual rats were placed in shock chambers (Coulbourn 
Habitest cages equipped with grid floors (Model E10-18RF) that were housed in 
Coulbourn Isolation Cubicles (Model HI0-23)). The rats were allowed to freely explore 
the shock chamber for 5 minutes, after which they were presented with 20 footshocks 
(0.8 mA, 0.5-second duration) at 1.0-minute intervals over the course of 20 minutes. Five 
minutes after the last shock, the rats were returned to their home cages and connected to 
the cables for sleep recording. 
The day following shock training, the rats were microinjected into the BA with either 
LY34 or vehicle. Then they were returned to the shock chambers and allowed to freely 
exploring the chamber for 1 hour for extinction training. The next day the rats were put in 
the same chamber for the test of extinction effects (test day). Eight days following the test 
day, rats were returned to the same chamber for the test of their recall of fear for the 
context (retest day). The shock chambers were thoroughly cleaned with diluted alcohol 
following each training or test session. 
Each session was videotaped using mini video cameras (Weldex, WDH-2500BS, 
3.6mm-lens) attached to the center ceiling of the shock chamber. 
All experimental procedures were conducted in the fourth hour of the light period, so 
the sleep recording started from the beginning of the fifth hour of light period. Sleep was 
recorded for 20 hour following each training/test session. 
4.5. Analysis of Freezing 
Freezing behavior, defined as the absence of body movement except for respiration, 
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was visually determined from the videotapes by a trained observer. Freezing was scored 
in 5-second intervals during each observation time block periods over the course of the 
recording period when the rats were placed in the shock chamber. During shock training, 
the preshock and postshock periods were scored for freezing (the first and last 5 minutes 
of the recording). During shock presentation, freezing was scored following shock 
presentations. For test and retest of contextual fear, freezing was scored over 30 minutes. 
For the extinction training, freezing was scored for four 15 minutes periods. The freezing 
time percentage (freezing time/total time x 100%) was calculated for each animal. 
4.6. Sleep Recording 
Sleep recording was performed with rats in their homecages placed in a chamber 
equipped for electrophysiological recording. A lightweight, shielded cable was connected 
to the plug in the rats' head. The cable was connected to a swivel that allowed free 
movement for the rats within their cages. EEG and EMG signals were processed by a 
Grass Model 12 polygraph equipped with model 12A5 amplifier and routed to an A/D 
board (Eagle PC30) housed in a Pentium class PC. The signal were digitized at 128 HZ 
and collected in 10-second epochs using a custom sleep data collection program. 
4.7. Determination of Sleep 
The EEG and EMG records were visually scored by a trained observer to 
determine wakefulness, NREM and REM in 10-second epochs (Sanford et al, 2002). 
Wakefulness was determined by the presence of low-voltage, fast EEG; high-amplitude, 
tonic EMG levels; and phasic EMG bursts that could be associated with gross body 
movements. NREM was scored by the presence of spindles interspersed with slow waves, 
lower muscle tone, and no gross body movements. REM was determined by the presence 
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of low-voltage, fast EEG, theta rhythm, and muscle atonia. 
4.8. Data Analysis 
Statistical analyses were conducted using SigmaStat (SPSS, Inc., Chicago, Illinois). 
Two-way ANOVAs across drug treatment and 4 h blocks were used to analyze freezing 
behavior. For comparison of sleep data between groups in each training day, one way 
ANOVAs were used for each 4 h block. For comparison of sleep data across training day 




The amygdala has been found to be implicated in the emotional modulation of sleep 
(Chapter I). The BA is a specific amygdaloid area that receives sensory inputs and 
projects to the CNA and the BNST, which have direct connections with hypothalamic and 
brainstem areas involved in the regulation of sleep and stress. In this study, we propose 
that the BA is an essential brain area involved in the regulation of normal sleep and in 
stress-induced alterations in sleep, and that mGlu II receptors could play a direct role in 
such regulation. Therefore, as discussed in chapter II, the specific mGlu II receptor 
agonist LY37 or antagonist LY34 was microinjected into the BA. 
LY35 may be safely microinjected into the amygdala at millimolar concentrations 
(Walker et al., 2002). Since LY37 is a derivative of LY35 and has similar characteristics, 
we assumed that LY37 could be safely injected into the BA at millimolar levels. We 
found that injection of LY37 suppressed REM without affecting NREM and wakefulness. 
However, we did not observe any dosage response. It has been reported that the affinity 
of LY37 for mGlu II receptors can be determined by evaluating its ability to displace 
radio-labeled antagonist LY34 (Monn et al., 1999). LY37 binds mGlu II receptors with a 
high affinity (IC50=10 nM) to mGlu II receptors in rat brain homogenates (Imre, 2007). 
Since mGlu II receptors are negatively coupled to adenylate cyclases, the ability of LY37 
to suppress forskolin-stimulated cAMP production is another important parameter for the 
pharmacological characteristics of LY37 (Monn et al., 1999). It has been reported that 
LY37 suppresses cAMP production in cells expressing human mGlu2 receptors (EC50=3 
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nM) and mGlu3 receptors (EC50=6 nM) (Imre, 2007). These data suggest that LY37 has 
a high affinity for mGlu II receptors. Therefore, we reduced drug concentrations to 
nanomolar levels and observed a dose-dependent response. This result is consistent with 
the high affinity of mGlu II receptors ligands. Therefore, for the antagonist experiments, 
we injected LY34 at nanomolar levels and observed increased arousal accompanied by 
suppression of REM and NREM in a dose-dependent manner. These data support the 
conclusion that the BA is an important brain area for the regulation of sleep by mGlu II 
receptors. 
The B A is also implicated in conditioned fear and fear extinction (Davis and Whalen, 
2001; Sotres-Bayon et al., 2004). Therefore, as discussed in chapter III, animals received 
a microinjection of LY34 (30 nM) or vehicle alone into the BA prior to extinction training 
and subsequent recording of their behavior and sleep. It was found that with the injection 
of LY34, the animals demonstrated less fear responses after extinction training compared 
to the control group. It was also found that the LY34 treated animals had increased REM 
following extinction training and testing. Since the microinjection of LY34 alone 
suppressed REM, extinction training may be the factor that induced the increase of REM. 
These data confirmed that fear and fear extinction could have an impact on the 
subsequent sleep, especially REM. 
Therefore, we conclude that the BA plays a role in the regulation of sleep and that 
mGlu II receptors in the BA are important in that regulation. Moreover, the BA is also an 
area involved in conditioned fear and fear extinction. Manipulation of the B A by mGlu II 
receptor agents could have a direct impact on extinction effects and subsequent sleep. 
Although the exact mechanisms are still unclear, a generally accepted hypothesis is that 
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mGlu II receptors serve as autoreceptors and function primarily during high glutamate 
release. We propose that injection of LY37 produces no significant alteration in glutamate 
release but suppresses GABA release (Anwyl, 1999; Cartmell and Schoepp, 2000; 
Smolders et al., 2004). It is the decrease in GABA associated with specific neuronal 
circuitry in the BA, the ITC and the CNA that contributes to the suppression of REM. 
Moreover, mGlu II receptors may maintain a tonic activity for modulating glutamate 
release (Linden et al., 2005). Suppression of mGlu II receptors by LY34 may shift 
glutamate release to a higher level and thus increase neuronal activity in the BA. This 
may be the reason that injection of LY34 in the BA increased arousal and suppressed 
REM and NREM. This increased neuronal activity in the BA may also contribute to the 
enhanced learning of extinction training, which may be responsible for the increased 
REM during the extinction day and testing day. 
Altogether, this study for the first time identified the BA as a potential brain area 
through which mGlu II receptors could regulate sleep. The combination of the mGlu II 
antagonist LY34 with extinction training ameliorated fear responses and sleep 
disturbances following conditioned fear. This may provide new prospects for the 
development of treatments for anxiety disorders, such as PTSD. 
Through the current studies we found that mGlu II receptors are involved in the 
regulation of sleep and stress-induced alterations in sleep. We proposed two separate 
pathways as indicated in Fig. 21 and Fig. 22 to explore the possible underlying 
mechanism. As illustrated in Fig. 21, microinjection of LY37 in the BA suppresses 
GABA release, which in turn suppresses the interneuron activity. The pyramidal neurons 







Fig. 21 - Proposed pathway by which microinjection of LY37 regulates REM through the 
BA. Microinjection of LY37 suppresses GABA release in the BA, which suppresses the 
activity of interneurons in the BA. The pyramidal neurons in the BA receive decreased 
inhibitory inputs from interneurons and send increased excitatory signals to intercalated 
cells. Therefore the BA sends increased excitatory outputs to intercalated cells. 
Intercalated cells in turn send increased inhibitory signals to the CNA and suppress REM. 









Fig. 22 - Proposed pathway by which microinjection of LY34 and extinction training 
regulate fear responses and sleep. Microinjection of LY34 increases neuronal activity in 
the BA, which suppresses REM and increase arousal through the CNA pathway as well 
as suppresses NREM through the hypothalamus. The increased neuronal activity in the 
BA may also facilitate fear extinction learning which may be responsible for the 
enhanced REM following extinction training and testing. ITC: intercalated cells. 
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excitatory signals to intercalated cells. Therefore the BA sends increased excitatory 
outputs to intercalated cells. Intercalated cells in turn send increased inhibitory signals to 
the CNA and suppress REM. As illustrated in Fig. 22, microinjection of LY34 increases 
neuronal activity in the BA, which suppresses REM and increases arousal through a CNA 
pathway as well as suppresses NREM through the hypothalamus. The increased neuronal 
activity in the BA may also facilitate fear extinction learning which may be responsible 
for the enhanced REM following extinction training and testing. These pathways are 
presented according to currently available evidence in the literature. Therefore, for future 
directions, we would like to expand the investigation by exploring the underlying 
mechanism of the behavioral observations. We would like to analyze the cell activity 
level in the BA after injection of LY37 by using c-Fos staining. The cells would be 
grouped into three categories: pyramidal cells, interneurons and intercalated neurons. The 
c-Fos expression level would be analyzed in these three types of cells to determine any 
change compared to the baseline. We would also like to perform electrophysiological 
recording of specific cell types prior to or after injection of LY37 or LY34 to determine 
the effects of the drug. 
81 
REFERENCES 
Ahnaou, A., Dautzenberg, F.M., et al., 2009. Modulation of group II metabotropic 
glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake 
architecture. Eur. J. Pharmacol. 603 (1-3), 62-72. 
al Maskati, H.A., Zbrozyna, A.W., 1989. Cardiovascular and motor components of the 
defence reaction elicited in rats by electrical and chemical stimulation in 
amygdala. J. Auton. Nerv. Syst. 28 (2), 127-131. 
Anwyl, R., 1999. Metabotropic glutamate receptors: electrophysiological properties and 
role in plasticity. Brain Res. Brain Res. Rev. 29 (1), 83-120. 
Benca, R.M., Obermeyer, W.H., et al., 1992. Sleep and psychiatric disorders. A 
meta-analysis. Arch. Gen. Psychiatry 49 (8), 651-668; discussion 669-670. 
Bergink, V., Megen, H.J., et al., 2004. Glutamate and anxiety. Eur. 
Neuropsychopharmacol. 14(3), 175-183. 
Blanchard, R.J., Blanchard, D.C., 1969. Crouching as an index of fear. J. Comp. Physiol. 
Psychol. 67 (3), 370-375. 
Blanchard, R.J., Blanchard, D.C., 1969. Passive and active reactions to fear-eliciting 
stimuli. J. Comp. Physiol. Psychol. 68 (1), 129-135. 
Bouton, M.E., 2002. Context, ambiguity, and unlearning: sources of relapse after 
behavioral extinction. Biol. Psychiatry 52 (10), 976-986. 
Calvo, J.M., Simon-Arceo, K., et al., 1996. Prolonged enhancement of REM sleep 
produced by carbachol microinjection into the amygdala. Neuroreport 7 (2), 
577-580. 
Canteras, N.S., Swanson, L.W., 1992. Projections of the ventral subiculum to the 
amygdala, septum, and hypothalamus: a PHAL anterograde tract-tracing study in 
the rat. J. Comp. Neurol. 324 (2), 180-194. 
Cartmell, J., Schoepp, D.D., 2000. Regulation of neurotransmitter release by 
metabotropic glutamate receptors. J. Neurochem. 75 (3), 889-907. 
Collins, D.R., Pare, D., 1999. Spontaneous and evoked activity of intercalated amygdala 
neurons. Eur. J. Neurosci. 11 (10), 3441-3448. 
Conn, P.J., Pin, J.P., 1997. Pharmacology and functions of metabotropic glutamate 
receptors. Annu. Rev. Pharmacol. Toxicol. 37, 205-237. 
82 
Cooper, J.B., Roth, R., 2003. Amino acid transmitters. New York, Oxford university 
press. 
Cortese, B.M., Phan, K.L., 2005. The role of glutamate in anxiety and related disorders. 
CNS. Spectr. 10 (10), 820-830. 
Davis, M, 1997. Neurobiology of fear responses: the role of the amygdala. J. 
Neuropsychiatry Clin. Neurosci. 9 (3), 382-402. 
Davis, M., 2000. The role of amygdala in conditioned and unconditioned fear and anxiety. 
New York, Oxford university press. 
Davis, M., Whalen, P.J., 2001. The amygdala: vigilance and emotion. Mol. Psychiatry. 6 
(1), 13-34. 
Deboer, T., Ross, R.J., et al., 1999. Electrical stimulation of the amygdala increases the 
amplitude of elicited ponto-geniculo-occipital waves. Physiol. Behav. 66 (1), 
119-124. 
Doyere, V., Gisquet-Verrier, P., et al., 2000. Age-related modifications of contextual 
information processing in rats: role of emotional reactivity, arousal and testing 
procedure. Behav. Brain Res. 114 (1-2), 153-165. 
Dringenberg, H.C., Vanderwolf, C.H., 1996. Cholinergic activation of the 
electrocorticogram: an amygdaloid activating system. Exp. Brain Res. 108 (2), 
285-296. 
Fanselow, M.S., LeDoux, J.E., 1999. Why we think plasticity underlying Pavlovian fear 
conditioning occurs in the basolateral amygdala. Neuron 23 (2), 229-232. 
Farb, C.R., Aoki, C , et al., 1995. Differential localization of NMDA and AMPA receptor 
subunits in the lateral and basal nuclei of the amygdala: a light and electron 
microscopic study. J. Comp. Neurol. 362 (1), 86-108. 
Feinberg, I., Campbell, I.G., et al., 2002. The selective group mGlu2/3 receptor agonist 
LY379268 suppresses REM sleep and fast EEG in the rat. Pharmacol. Biochem. 
Behav. 73 (2), 467-474. 
Feinberg, I., Schoepp, D.D., et al., 2005. The metabotropic glutamate (mGLU)2/3 
receptor antagonist LY341495 
[2S-2-amino-2-(lS,2S-2-carboxycyclopropyl-l-yl)-3-(xanth-9-yl) propanoic acid] 
stimulates waking and fast electroencephalogram power and blocks the effects of 
the mGLU2/3 receptor agonist ly379268 
[(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats. J. Pharmacol. 
Exp. Ther. 312(2), 826-833. 
83 
Feindel, W., Penfield, W., 1954. Localization of discharge in temporal lobe automatism. 
AMA. Arch. Neurol. Psychiatry 72 (5), 603-630. 
File, S., 2000. The amygdala: anxiety and benzodiazepines. New York, Oxford university 
press. 
Foa, E.B., 2006. Psychosocial therapy for posttraumatic stress disorder. J. Clin. 
Psychiatry 67 Suppl. 2, 40-45. 
Fontella, F.U., Vendite, D.A., et al., 2004. Repeated restraint stress alters hippocampal 
glutamate uptake and release in the rat. Neurochem. Res. 29 (9), 1703-1709. 
Gale, G.D., Anagnostaras, S.G., et al., 2004. Role of the basolateral amygdala in the 
storage of fear memories across the adult lifetime of rats. J. Neurosci. 24 (15), 
3810-3815. 
Gelsema, A. J., McKitrick, D.J., et al., 1987. Cardiovascular responses to chemical and 
electrical stimulation of amygdala in rats. Am. J. Physiol. 253 (5 Pt 2), R712-718. 
Germain, A., Buysse, D.J., et al., 2008. Sleep-specific mechanisms underlying 
posttraumatic stress disorder: integrative review and neurobiological hypotheses. 
Sleep Med. Rev. 12 (3), 185-195. 
Gilad, G.M., Gilad, V.H., et al., 1990. Region-selective stress-induced increase of 
glutamate uptake and release in rat forebrain. Brain Res. 525 (2), 335-338. 
Grillon, C , Cordova, J., et al., 2003. Anxiolytic effects of a novel group II metabotropic 
glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in 
humans. Psychopharmacology (Berl) 168 (4), 446-454. 
Helton, D.R., Tizzano, J.P., et al., 1998. Anxiolytic and side-effect profile of LY354740: 
a potent, highly selective, orally active agonist for group II metabotropic 
glutamate receptors. J. Pharmacol. Exp. Ther. 284 (2), 651-660. 
Hetzenauer, A., Corti, C , et al., 2008. Individual contribution of metabotropic glutamate 
receptor (mGlu) 2 and 3 to c-Fos expression pattern evoked by mGlu2/3 
antagonism. Psychopharmacology (Berl) 201 (1), 1-13. 
Higgins, G.A., Ballard, T.M., et al., 2004. Pharmacological manipulation of mGlu2 
receptors influences cognitive performance in the rodent. Neuropharmacology 46 
(7), 907-917. 
Holland, P.C., Han, J.S., et al., 2000. Lesions of the amygdala central nucleus alter 
performance on a selective attention task. J. Neurosci. 20 (17), 6701-6706. 
84 
Ikegaya, Y., Saito, H., et al., 1994. Attenuated hippocampal long-term potentiation in 
basolateral amygdala-lesioned rats. Brain Res. 656 (1), 157-164. 
Imre, G., 2007. The preclinical properties of a novel group II metabotropic glutamate 
receptor agonist LY379268. CNS. Drug. Rev. 13 (4), 444-464. 
Jasper, H.H., Khan, R.T., et al., 1965. Amino Acids Released from the Cerebral Cortex in 
Relation to Its State of Activation. Science 147, 1448-1449. 
Jha, S.K., Brennan, F.X., et al., 2005. REM sleep: a sensitive index of fear conditioning 
in rats. Eur. J. Neurosci. 21 (4), 1077-1080. 
Jones, B., 2005. Basic Mechanism of Sleep-Wake States. Philadelphia, Elesvier 
Saunders. 
Kew, J.N., Ducarre, J.M., et al., 2001. Activity-dependent presynaptic autoinhibition by 
group II metabotropic glutamate receptors at the perforant path inputs to the 
dentate gyrus and CA1. Neuropharmacology 40 (1), 20-27. 
Kim, J.J., Lee, H.J., et al., 2001. Amygdala is critical for stress-induced modulation of 
hippocampal long-term potentiation and learning. J. Neurosci. 21 (14), 
5222-5228. 
Kingston, A.E., Ornstein, P.L., et al., 1998. LY341495 is a nanomolar potent and 
selective antagonist of group II metabotropic glutamate receptors. 
Neuropharmacology 37 (1), 1-12. 
Kodama, T., Lai, Y.Y., et al., 1998. Enhanced glutamate release during REM sleep in the 
rostromedial medulla as measured by in vivo microdialysis. Brain Res. 780 (1), 
178-181. 
Korte, S.M., Koolhaas, J.M., et al., 2005. The Darwinian concept of stress: benefits of 
allostasis and costs of allostatic load and the trade-offs in health and disease. 
Neurosci. Biobehav. Rev. 29 (1), 3-38. 
Krettek, J.E., Price, J.L., 1978. Amygdaloid projections to subcortical structures within 
the basal forebrain and brainstem in the rat and cat. J. Comp. Neurol. 178 (2), 
225-254. 
Kunishima, N., Shimada, Y., et al., 2000. Structural basis of glutamate recognition by a 
dimeric metabotropic glutamate receptor. Nature 407 (6807), 971-977. 
LeDoux, J.E., 1992. Brain mechanisms of emotion and emotional learning. Curr. Opin. 
Neurobiol. 2(2), 191-197. 
LeDoux, J.E., 2000. Emotion circuits in the brain. Annu. Rev. Neurosci. 23, 155-84. 
85 
LeDoux, J.E., Cicchetti, P., et al., 1990. The lateral amygdaloid nucleus: sensory 
interface of the amygdala in fear conditioning. J.Neurosci.10 (4), 1062-1069. 
Lee, H., Kim, J.J., 1998. Amygdalar NMDA receptors are critical for new fear learning in 
previously fear-conditioned rats. J. Neurosci. 18 (20), 8444-8454. 
Linden, A.M., Bergeron, M., et al., 2005. Comparison of c-Fos induction in the brain by 
the mGlu2/3 receptor antagonist LY341495 and agonist LY354740: evidence for 
widespread endogenous tone at brain mGlu2/3 receptors in vivo. 
Neuropharmacology 49 Suppl. 1, 120-134. 
Lorrain, D.S., Baccei, C.S., et al., 2003. Effects of ketamine and N-methyl-D-aspartate on 
glutamate and dopamine release in the rat prefrontal cortex: modulation by a 
group II selective metabotropic glutamate receptor agonist LY379268. 
Neuroscience 117 (3), 697-706. 
Lorrain, D.S., Baccei, C.S., et al., 2005. Comparison of the effects of diazepam, the 
CRFT antagonist CP-154,526 and the group II mGlu receptor agonist LY379268 
on stress-evoked extracellular norepinephrine levels. Neuropharmacology 48 (7), 
927-935. 
Lowy, M.T., Wittenberg, L., et al., 1995. Effect of acute stress on hippocampal glutamate 
levels and spectrin proteolysis in young and aged rats. J. Neurochem. 65 (1), 
268-274. 
Lujan, R., Roberts, J. D., et al., 1997. Differential plasma membrane distribution of 
metabotropic glutamate receptors mGluRl alpha, mGluR2 and mGluR5, relative 
to neurotransmitter release sites. J. Chem. Neuroanat. 13 (4), 219-241. 
Maren, S., Aharonov, G., et al., 1996. Retrograde abolition of conditional fear after 
excitotoxic lesions in the basolateral amygdala of rats: absence of a temporal 
gradient. Behav. Neurosci. 110 (4), 718-726. 
Maren, S., Aharonov, G., et al., 1997. Neurotoxic lesions of the dorsal hippocampus and 
Pavlovian fear conditioning in rats. Behav. Brain Res. 88 (2), 261-274. 
Maren, S., Fanselow, M.S., 1995. Synaptic plasticity in the basolateral amygdala induced 
by hippocampal formation stimulation in vivo. J. Neurosci. 15(11), 7548-7564. 
Mayer, M.L., Westbrook, G.L., 1987. The physiology of excitatory amino acids in the 
vertebrate central nervous system. Prog. Neurobiol. 28 (3), 197-276. 
McDonald, A. J., 1992. Projection neurons of the basolateral amygdala: a correlative 
Golgi and retrograde tract tracing study. Brain Res. Bull. 28 (2), 179-185. 
86 
McDonald, A. J., Mascagni, F., et al., 1996. Projections of the medial and lateral 
prefrontal cortices to the amygdala: a Phaseolus vulgaris leucoagglutinin study in 
the rat. Neuroscience 71 (1), 55-75. 
Milad, M.R., Quirk, G.J., 2002. Neurons in medial prefrontal cortex signal memory for 
fear extinction. Nature 420 (6911), 70-74. 
Millhouse, O.E., 1986. The intercalated cells of the amygdala. J. Comp. Neurol. 247 (2), 
246-271. 
Mineff, E., Valtschanoff, J., 1999. Metabotropic glutamate receptors 2 and 3 expressed 
by astrocytes in rat ventrobasal thalamus. Neurosci. Lett. 270 (2), 95-98. 
Moepps, B., Fagni, L., 2003. Mont Sainte-Odile: a sanctuary for GPCRs. Confidence on 
signal transduction of G-protein-couple receptors. EMBO. Rep. 4 (3), 237-243. 
Monaghan, D.T., Bridges, R.J., et al., 1989. The excitatory amino acid receptors: their 
classes, pharmacology, and distinct properties in the function of the central 
nervous system. Annu. Rev. Pharmacol. Toxicol. 29, 365-402. 
Monn, J.A., Valli, M.J., et al , 1999. Synthesis, pharmacological characterization, and 
molecular modeling of heterobicyclic amino acids related to 
(+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): 
identification of two new potent, selective, and systemically active agonists for 
group II metabotropic glutamate receptors. J. Med. Chem. 42 (6), 1027-1040. 
Monn, J.A., Valli, M.J., et al., 1997. Design, synthesis, and pharmacological 
characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 
(LY3 54740): a potent, selective, and orally active group 2 metabotropic glutamate 
receptor agonist possessing anticonvulsant and anxiolytic properties. J. Med. 
Chem. 40 (4), 528-537. 
Morrison, A.R., Sanford, L.D., et al., 2000. The amygdala: a critical modulator of sensory 
influence on sleep. Biol. Signals Recept. 9 (6), 283-296. 
Myers, K.M., Davis, M., 2007. Mechanisms of fear extinction. Mol. Psychiatry 12 (2), 
120-150. 
Narabayashi, H., Nagao, T., et al., 1963. Stereotaxic amygdalotomy for behavior 
disorders. Arch. Neurol. 9, 1-16. 
Nitecka, L., Ben-Ari, Y., 1987. Distribution of GABA-like immunoreactivity in the rat 
amygdaloid complex. J. Comp. Neurol. 266 (1), 45-55. 
87 
O'Neill, M.F., Heron-Maxwell, C , et al., 2003. Group II metabotropic glutamate receptor 
antagonists LY341495 and LY366457 increase locomotor activity in mice. 
Neuropharmacology 45 (5), 565-574. 
Ohishi, H., Shigemoto, R., et al., 1993. Distribution of the messenger RNA for a 
metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. 
Neuroscience 53 (4), 1009-1018. 
Ohishi, H., Shigemoto, R., et al., 1993. Distribution of the mRNA for a metabotropic 
glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J. 
Comp. Neurol. 335 (2), 252-266. 
Onishi BK., Xavier. G., 2010. Contextual, but not auditory, fear conditioning is disrupted 
by neurotoxic selective lesion of the basal nucleus of amygdala in rats. Neurobiol. 
Learn. Mem. 93 (2), 165-174. 
Ono, T., Nishijo, H., et al., 1995. Amygdala role in conditioned associative learning. Prog. 
Neurobiol. 46 (4), 401-422. 
Ottersen, O.P., Landsend, A.S., 1997. Organization of glutamate receptors at the synapse. 
Eur. J. Neurosci. 9 (11), 2219-2224. 
Palucha, A., Pile, A., 2007. Metabotropic glutamate receptor ligands as possible 
anxiolytic and antidepressant drugs. Pharmacol. Ther. 115 (1), 116-147. 
Paxinos G, W.C., 1997. The rat brain in stereotaxic coordinates. San Diego, Academic 
press. 
Peri, T., Ben-Shakhar, G., et al., 2000. Psychophysiologic assessment of aversive 
conditioning in posttraumatic stress disorder. Biol. Psychiatry 47 (6), 512-519. 
Petralia, R.S., Wang, Y.X., et al., 1996. The metabotropic glutamate receptors, mGluR2 
and mGluR3, show unique postsynaptic, presynaptic and glial localizations. 
Neuroscience 71 (4), 949-976. 
Petrov, T., Krukoff, T.L., et al., 1994. Chemically defined collateral projections from the 
pons to the central nucleus of the amygdala and hypothalamic paraventricular 
nucleus in the rat. Cell Tissue Res. 277 (2), 289-295. 
Pitkanen, A., 2000. Connectivity of the rat amygdaloid complex. Oxford, Oxford 
University Presss. 
Pitkanen, A., Amaral, D.G., 1994. The distribution of GABAergic cells, fibers, and 
terminals in the monkey amygdaloid complex: an immunohistochemical and in 
situ hybridization study. J. Neurosci. 14 (4), 2200-2224. 
88 
Pitman, R.K., 1997. Overview of biological themes in PTSD. Ann. N. Y. Acad. Sci. 821, 
1-9. 
Quirk, G.J., Gehlert, D.R., 2003. Inhibition of the amygdala: key to pathological states? 
Ann. N. Y. Acad. Sci. 985, 263-272. 
Quirk, G.J., Likhtik, E., et al., 2003. Stimulation of medial prefrontal cortex decreases the 
responsiveness of central amygdala output neurons. J. Neurosci. 23 (25), 
8800-8807. 
Quirk, G.J., Mueller, D., 2008. Neural mechanisms of extinction learning and retrieval. 
Neuropsychopharmacology 33 (1), 56-72. 
Quirk, G.J., Russo, G.K., et al., 2000. The role of ventromedial prefrontal cortex in the 
recovery of extinguished fear. J. Neurosci. 20 (16), 6225-6231. 
Rainnie, D.G., Asprodini, E.K., et al., 1991. Inhibitory transmission in the basolateral 
amygdala. J. Neurophysiol. 66 (3), 999-1009. 
Roozendaal, B., Sapolsky, R.M., et al., 1998. Basolateral amygdala lesions block the 
disruptive effects of long-term adrenalectomy on spatial memory. Neuroscience 
84 (2), 453-465. 
Rosenkranz, J.A., Grace A.A., 2001. Dopamine attenuates prefrontal cortical suppression 
of sensory inputs to the basolateral amygdala of rats. J. Neurosci. 21 (11), 
4090-4103. 
Royer, S., Martina, M., et al. (1999). An inhibitory interface gates impulse traffic 
between the input and output stations of the amygdala. J. Neurosci. 19 (23), 
10575-83. 
Sah, P., Faber, E.S., et al., 2003. The amygdaloid complex: anatomy and physiology. 
Physiol. Rev. 83 (3), 803-834. 
Sanford, L.D., Nassar, P., et al., 1998 . Prolactin microinjections into the amygdalar 
central nucleus lead to decreased NREM sleep. Sleep Res. Online 1 (3): 109-113. 
Sanford, L.D., Parris, B., et al., 2002. GABAergic regulation of the central nucleus of the 
amygdala: implications for sleep control. Brain Res. 956 (2), 276-284. 
Sanford, L.D., Silvestri, A.J., et al., 2001. Influence of fear conditioning on elicited 
ponto-geniculo-occipital waves and rapid eye movement sleep. Arch. Ital. Biol. 
139(3), 169-183. 
89 
Sanford, L.D., Tejani-Butt, S.M., et al., 1995. Amygdaloid control of alerting and 
behavioral arousal in rats: involvement of serotonergic mechanisms. Arch. Ital. 
Biol. 134(1), 81-99. 
Sanford, L.D., Yang, L., et al., 2003. Influence of contextual fear on sleep in mice: a 
strain comparison. Sleep 26 (5), 527-540. 
Sanford, L.D., Yang, L., et al., 2006. Cholinergic regulation of the central nucleus of the 
amygdala in rats: effects of local microinjections of cholinomimetics and 
cholinergic antagonists on arousal and sleep. Neuroscience 141 (4), 2167-2176. 
Sarter, M., Markowitsch, H. J., 1985. The amygdala's role in human mnemonic 
processing. Cortex 21 (1), 7-24. 
Sateia, M.J., 2009. Update on sleep and psychiatric disorders. Chest 135 (5), 1370-1379. 
Scaccianoce, S., Matrisciano, F., et al., 2003. Endogenous activation of group-II 
metabotropic glutamate receptors inhibits the 
hypothalamic-pituitary-adrenocortical axis. Neuropharmacology 44 (5), 555-561. 
Scanziani, M., Salin, P.A., et al., 1997. Use-dependent increases in glutamate 
concentration activate presynaptic metabotropic glutamate receptors. Nature 385 
(6617), 630-634. 
Scheel-Kruger, J., Petersen, E.N., 1982. Anticonflict effect of the benzodiazepines 
mediated by a GABAergic mechanism in the amygdala. Eur. J. Pharmacol. 82 
(1-2), 115-116. 
Schwendt, M., Jezova, D., 2000. Gene expression of two glutamate receptor subunits in 
response to repeated stress exposure in rat hippocampus. Cell Mol. Neurobiol. 20 
(3), 319-329. 
Shalev, A.Y., Ragel-Fuchs, Y., et al., 1992. Conditioned fear and psychological trauma. 
Biol. Psychiatry 31 (9), 863-865. 
Shekhar, A., Keim, S.R., 2000. LY354740, a potent group II metabotropic glutamate 
receptor agonist prevents lactate-induced panic-like response in panic-prone rats. 
Neuropharmacology 39 (7), 1139-1146. 
Shigemoto, R., Kinoshita, A., et al., 1997. Differential presynaptic localization of 
metabotropic glutamate receptor subtypes in the rat hippocampus. J. Neurosci. 17 
(19), 7503-7522. 
Shimazaki, T., Kaku, A., et al., 2007. Blockade of the metabotropic glutamate 2/3 
receptors enhances social memory via the AMPA receptor in rats. Eur. J. 
Pharmacol. 575(1-3), 94-97. 
90 
Shinonaga, Y., Takada, M., et al., 1994. Topographic organization of collateral 
projections from the basolateral amygdaloid nucleus to both the prefrontal cortex 
and nucleus accumbens in the rat. Neuroscience 58 (2), 389-397. 
Siegel, J., 2005. REM sleep. Philadephia, Elsevier Saunders. 
Smith, C.T., Miskiman, D.E., 1975. Increases in paradoxical sleep as a result of 
amygdaloid stimulation. Physiol. Behav. 15 (1), 17-19. 
Smith, Y., Pare, D., 1994. Intra-amygdaloid projections of the lateral nucleus in the cat: 
PHA-L anterograde labeling combined with postembedding GABA and glutamate 
immunocytochemistry. J. Comp. Neurol. 342 (2), 232-248. 
Smith, Y., Pare, J.F., et al., 2000. Differential innervation of 
parvalbumin-immunoreactive interneurons of the basolateral amygdaloid complex 
by cortical and intrinsic inputs. J. Comp. Neurol. 416 (4), 496-508. 
Smolders, I., Lindekens, H., et al., 2004. In vivo modulation of extracellular hippocampal 
glutamate and GABA levels and limbic seizures by group I and II metabotropic 
glutamate receptor ligands. J. Neurochem. 88 (5), 1068-1077. 
Sotres-Bayon, F., Bush, D.E., et al., 2004. Emotional perseveration: an update on 
prefrontal-amygdala interactions in fear extinction. Learn. Mem. 11 (5), 525-35. 
Swanson, C.J., Bures, M., et al., 2005. Metabotropic glutamate receptors as novel targets 
for anxiety and stress disorders. Nat. Rev. Drug Discov. 4 (2), 131-144. 
Takeuchi, Y., McLean, J.H., et al., 1982. Reciprocal connections between the amygdala 
and parabrachial nuclei: ultrastructural demonstration by degeneration and axonal 
transport of horseradish peroxidase in the cat. Brain Res. 239 (2), 583-588. 
Tamaru, Y., Nomura, S., et al., 2001. Distribution of metabotropic glutamate receptor 
mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic 
sites. Neuroscience 106 (3), 481-503. 
Tang, X., Yang, L., et al., 2005. Influence of tetrodotoxin inactivation of the central 
nucleus of the amygdala on sleep and arousal. Sleep 28 (8), 923-930. 
Tang, X., Yang, L., et al., 2005. Rat strain differences in freezing and sleep alterations 
associated with contextual fear. Sleep 28 (10), 1235-1244. 
Toyomitsu, Y., Nishijo, H., et al., 2002. Neuronal responses of the rat amygdala during 
extinction and reassociation learning in elementary and configural associative 
tasks. Eur. J. Neurosci. 15 (4), 753-768. 
91 
Wada, E., Shigemoto, R., et al., 1998. Metabotropic glutamate receptor subtypes in axon 
terminals of projection fibers from the main and accessory olfactory bulbs: a light 
and electron microscopic immunohistochemical study in the rat. J. Comp. Neurol. 
393 (4), 493-504. 
Walker, D.L., Rattiner, L.M., et al., 2002. Group II metabotropic glutamate receptors 
within the amygdala regulate fear as assessed with potentiated startle in rats. 
Behav. Neurosci. 116 (6), 1075-1083. 
Washburn, M.S., Moises H.C., 1992. Electrophysiological and morphological properties 
of rat basolateral amygdaloid neurons in vitro. J. Neurosci. 12(10), 4066-4079. 
Wellman, L.L., Yang, L., et al., 2008. Contextual fear extinction ameliorates sleep 
disturbances found following fear conditioning in rats. Sleep 31 (7), 1035-1042. 
Wright, R.A., Arnold, M.B., et al., 2001. [3H]LY341495 binding to group II 
metabotropic glutamate receptors in rat brain. J. Pharmacol. Exp. Ther. 298 (2), 
453-460. 
Yaniv, D., Richter-Levin, G., 2000. LTP in the rat basal amygdala induced by perirhinal 
cortex stimulation in vivo. Neuroreport 11 (3), 525-530. 
Yokoi, M, Kobayashi, K., et al., 1996. Impairment of hippocampal mossy fiber LTD in 
mice lacking mGluR2. Science 273 (5275), 645-647. 
Zhu, G.Q., Zhong, M.K., et al., 1998. Role of basolateral amygdaloid nuclei in sleep and 




Department of Pathology and Anatomy 
Eastern Virginia Medical School 
Norfolk, VA 23501 
Education: 
2010 Ph.D. in Biomedical Sciences 
Eastern Virginia Medical School 
Norfolk, VA 
2000 B. S. in Biotechnology 
Xiamen University 
Xiamen, Fujian, China 
Manuscripts in preparation 
Enheng Dong, Laurie Wellman, Linghui Yang, and Larry Sanford. Group II 
Metabotropic Glutamate Receptors in the Basal Amygdala Regulate Sleep. 
Enheng Dong, Laurie Wellman, Linghui Yang, and Larry Sanford. Microinjection of 
Group II Metabotropic Glutamate Receptor Antagonist, LY341495, into the Basal 
Amygdala Facilitates Fear Extinction and Attenuates Fear-induced Alterations in Sleep. 
Publications: 
1. Sanford LD, Yang L, Wellman LL, Dong E, Tang X (2008). Mouse strain differences 
in the effects of corticotropin releasing hormone (CRH) on sleep and wakefulness. Brain 
Res 1190:94-104. 
2. Sanford LD, Yang L, Tang X, Dong E, Ross RJ, Morrison AR (2006). Cholinergic 
regulation of the central nucleus of the amygdala in rats: effects of local microinjections 
of cholinomimetics and cholinergic antagonists on arousal and sleep. Neuroscience 
141(4):2167-2176. 
Awards: 
2009 First Prize, Research Day Graduate Student Poster Presentation, 
Eastern Virginia Medical School 
